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ABSTRACT
Angiogenin (ANG) is a secreted protein that holds important implications in the growth
and survival for a variety of cell types—from healthy endothelial or neuronal cells, to diseased
cancer cells. Currently, we lack a complete understanding of ANG’s mechanism of action. Our
work aims to develop a functional fluorescence-based reporting system to study ANG
internalization activity in cancer cells. Specifically, we utilize a split green fluorescent protein
(split GFP) system, in which the 11th strand of the GFP molecule (GFP11) is attached to ANG,
while the remaining non-fluorescent GFP1-10 fragment is expressed in our target HeLaGFP1-10
cell line. The reconstitution of GFP1-10 and GFP11 will restore bright fluorescence signal,
indicating ANG’s successful cellular entry. The workflow of this project is two-fold: first, to
design, express and purify six variants of ANG-GFP11 proteins, and second, to characterize the
kinetics and internalization activity of these fusion proteins in HeLaGFP1-10 cells. We have
successfully produced three C-terminal ANG-GFP11 variants with robust ribonucleolytic
activities, and demonstrated their capacity to reconstitute GFP fluorescence. With these key tools
in place, we are now assessing the system’s efficiency in monitoring ANG uptake. If successful,
this split fluorescence system offers a powerful way to study ANG activity in the target cell line,
ultimately shedding more light on the role of ANG in cancer and other disease-related pathways.
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INTRODUCTION
Angiogenin
Angiogenin (ANG) is a secretory ribonuclease found in the blood and interstitial fluids of
most, but not all, vertebrates. ANG was first isolated in the 1980’s from human colon
adenocarcinoma,1 attracting attention in the scientific community for its ability to induce new
blood vessel formation, a process formally referred to as angiogenesis.1–3 Later on, it was also
found in human plasma,4 amniotic fluid,5 as well as cerebrospinal fluid.6 Research over the past
four decades has continued to unveil ANG structure and functions, underscoring its
physiological role in both the healthy and diseased states. Yet, much of ANG’s mechanism of
action remains unknown, and a more complete understanding of ANG is needed to fully
elucidate its versatile role in the cellular environment.
Structural characterizations
Angiogenin (ANG) is encoded by the ANG1 gene on human’s chromosome 14. The ANG
protein contains 123 amino acid residues and is 14.1kDa in size (Figure 1a).7,8 Its structure
consists of two α-helices, seven β-sheets and three disulfide bonds, which can be broken down
into three main catalytic subsites: one for pyrimidine binding (B1), one for purine binding (B2),
and one for phosphodiester bond cleavage (P1).9 In addition, ANG contains a nuclear localization
signal on the external face of the protein, distant to the active site. All of these structural features
are essential to ANG’s ribonucleolytic activity.

1

Italicized ANG indicates the gene encoding for angiogenin, whereas non-italicized ANG indicates the
protein angiogenin itself.
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Figure 1. Cartoon representation of angiogenin (ANG)’s crystal structure. (a) ANG’s surface is mapped in
grey mesh, while the catalytic residues (His-13, Lys-40, His-114 and Gln-117) are shown in red and orange.
(b) Ribbon representation of ANG, highlighting important residues: catalytic residues in the phosphate
cleavage site (His-13, Lys-40, His-114) represented as red sticks, the obstructive Gln-117 residue in the B1
binding site as orange sticks, nuclear localization signal (31Arg-Lys35) in yellow, and receptor binding site
(60Lys-Lys68) in blue. Crystal structure was obtained from PDB code 1B1I and visualized using PyMOL.

ANG is a member of the RNase A superfamily of proteins and, as such, shares many
structural similarities with other members in the superfamily. The RNase A superfamily consists
of eight members that hold diverse physiological roles in different tissues and cells, but all share
the ability to degrade RNA.10 Particularly, RNase A (bovine pancreatic ribonuclease) is the most
well-studied and renowned for its outstanding chemical stability.10 The amino acid sequence of
ANG is a close homologue to that of RNase A, with approximately 33% matching sequence
identity. However, the ribonucleolytic activity of ANG is far inferior compared to RNase A—
about 105 to 106 less than that of RNase A.11 This inferior catalytic activity can be attributed to
numerous structural differences, as follows.
Compared to RNase A, the B1 pyrimidine binding site of ANG is sterically hindered by
the residue Gln-117, whose side chain forms intramolecular hydrophobic interactions with
nearby residues Ile-119 and Phe-120 (Figure 1b).12 It is hypothesized that in order to enable its
ribonucleolytic activity, ANG needs to undergo a conformational change upon substrate binding
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to overcome this blockage. Conformational changes are energetically taxing, and previous
pyrimidine binding data suggests that this conformational change in ANG indeed has a high
energetic cost.12 Therefore, the steric block in ANG’s active site caused by Gln-117 is likely
responsible for the reduced catalytic activity of ANG.8,13
The presence or absence of hydrogen bonds also influences the catalytic activity of ANG.
Specifically, the formation of a hydrogen bond between Thr-44 and Thr-80 residues contributes
to the limited activity of the B1 pyrimidine binding site.8,14 On the other hand, the absence of a
hydrogen bond between residues His-119—Asp-121, which aids in catalysis in RNase A, also
contributes to ANG’s limited activity.
ANG also differs from RNase A in its number of disulfide bridges—ANG has three
paired disulfide bonds while RNase A has four. In ANG, disulfide bridges are formed between
residues 26-81, 39-92, and 57-197, lacking the fourth between the corresponding Cys-65—Cys70 residues of RNase A.7 In place of this fourth disulfide bond, the Lys-60 to Lys-68 residues in
ANG form a loop region to interact with cell surface receptor on target endothelial cells.15
In addition to these differences, the P1 phosphodiester cleavage site of ANG bears the
most similarity to that of RNase A. The catalytic triad contains His-13, Lys-40 and His-114
(Figure 1b),16 corresponding to RNase A’s residues His-12, Lys-41, and His-119.7 This triad
allows ANG to cleave the phosphodiester backbone of ribonucleotides via a general acid-base
mechanism, hence is essential for its ribonucleolytic activity.
Lastly, the structural similarities between ANG and RNase A also give rise to their
comparable thermal stability. Protein thermal stability is often quantified through its melting
temperature, Tm, which is defined as the temperature at which the protein denatures. RNase A
and ANG possess identical Tm values at 63.3°C, while the mutant variants of ANG linked to ALS
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have shown lower Tm values and thus lower thermal stability.17,18 ANG is therefore a relatively
stable protein under ambient laboratory conditions, which gives us confidence that it can be
stably expressed as a fusion protein in this work.
ANG is a versatile protein
While angiogenesis is indeed the most well-known function of ANG, ANG is also
involved in many other physiological pathways. For example, ANG demonstrates
neuroprotective19 and inflammatory activity,20 and contributes towards innate immunity,21
reproduction22 and regeneration of damaged tissues.23 Defective loss-of-function mutants of
ANG have also been identified in neurodegenerative diseases, like amyotrophic lateral sclerosis
(ALS) & Parkinson’s disease.24–26
Our work centers around examining the activity of ANG in angiogenesis and cancer cell
proliferation. Angiogenesis, or the formation of blood vessels, is typically induced by the
growth, proliferation, and migration of endothelial and smooth muscle cells. It is a tightly
regulated process involving a diverse group of proteins, such as vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), or
epidermal growth factor (EGF).23 Amongst these other angiogenic proteins, only ANG is a
secreted protein and must be internalized by a cell to promote its angiogenic function. At the
same time, it is the only angiogenic protein with ribonucleolytic activity. It is indeed a special
protein that deserves much scientific attention.
ANG in the cellular environment
The mechanism of ANG uptake has been especially elusive. One of the biggest
challenges in elucidating this mechanism is the identification of a cell surface receptor. As a
secretory protein, ANG needs to be internalized by its target cells in order to perform its myriad
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biological functions. The internalization activity of ANG is facilitated by the interaction between
the Lys-60—Lys-68 loop (Figure 1b), residue Asn-109, and a cell-surface receptor present on
endothelial and smooth muscle cells (Figure 2).27,28 Yu et al. recently identified that this receptor
is plexin-B2,29 a 170kDa protein that is only expressed in subconfluent and proliferative cells.30
In subconfluent cultures, the low cell density triggers the expression of the plexin-B2 receptor,
which then allows the cells to internalize ANG and subsequently undergo proliferation to
increase the cell density. Once the cell density reaches a certain threshold, expression of plexinB2 is turned off, and the internalization of ANG is temporarily halted.30 The activity of plexinB2 is therefore critical to the cellular functions of ANG.29
The wide array of ANG interactions in the cellular environments is portrayed in Figure
2.31 These activities do not occur separately, but are highly intermingled. For example, in the
case of injury or infection, healthy endothelial cells trigger ANG-mediated changes in gene
expression and cell structure, leading to angiogenesis and stimulating the healing process. On the
other hand, cancer cells can hijack this process to promote the growth of blood vessels towards
tumor cells and induce uncontrolled tumor growth. The full mechanism of action of ANG
remains to be elucidated; however, the following sections provide a summary of our current
knowledge of ANG’s role in angiogenesis and cellular proliferation.
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Figure 2. ANG’s mechanism of action. Secreted ANG can associate with actin molecules on the cell surface
to facilitate for cell migration. In order to be internalized, ANG interacts with a cell-surface receptor on
endothelial and smooth muscle cells. Once in the cytoplasm, ANG activates an array of signaling
pathways, such as SAPK/JNK, ERK1/2, and PI3K/AKT. If not bound by the inhibitor RNH1, it can cleave
tRNA’s to produce tiRNA’s as part of the cell’s stress response mechanism. In addition, ANG is translocated
to the nucleus via an unknown mechanism. In the nucleus, it can bind to rDNA to upregulate rRNA
production, stimulating ribosome biogenesis and ultimately enhancing cell growth.

RNA binding and catalysis
Similar to RNase A, ANG binds to and cleaves single-stranded ribonucleotides.
However, in contrast to RNase A’s promiscuity to cleave after any pyrimidine nucleotides, ANG
only cleaves at selected regions within a substrate.32 In the B1 pyrimidine-binding site, ANG
specifically cleaves the 3’-side of single-stranded pyrimidine nucleotides following a
phosphorylation-hydrolysis mechanism.7 Amongst pyrimidines, ANG prefers to interact with
cytidine over uridine by 10- to 30- fold. In contrast, the B2 purine binding site is less selective,
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with a preference for adenosine over guanosine by 3-fold.33 Taken together, the selectivity in
both binding sites gives rise to ANG’s lower kinetic profile compared to RNase A.
Role in cellular migration
Besides the Plexin-B2 receptor, ANG also interacts with a smooth muscle type alphaactin, a 42kDa cell-surface protein (Figure 2). This interaction is essential to the angiogenesis
process.34 Upon binding, the ANG-actin complex dissociates from the cell surface, thereby
triggering the formation of plasmin from plasminogen, as catalyzed by a tissue-type plasminogen
activator (tPA).35 This complex then promotes degradation of the basement membrane and the
ECM, thereby allowing endothelial cells to migrate and penetrate into the perivascular tissue.36
In new perivascular tissue, ANG can therefore encourage the formation of blood vessels.
Activity in the cytoplasm
ANG was first found to be cytotoxic upon injection into the cytoplasm, as it degraded
cellular RNA and eventually killed the cells.37,38 Given this observation, researchers set out to
identify the regulatory elements of ANG activity in the cellular space. This led to the discovery
of the tight binding between ANG and the human ribonuclease inhibitor (RNH1), an abundant
50kDa protein39 that can bind to ANG at Kd < 1fM.11,40 This binding is one of the tightest noncovalent protein:protein interactions known till this day, and is hypothesized to be the regulator
of ANG activity under different growth conditions41 (Figures 2, 3). Specifically, under growth
conditions, cytoplasmic ANG is bound tightly by RNH1 to prevent random transfer RNA
(tRNA) cleavage (Figure 2, 3a). In contrast, under stress conditions, cytoplasmic ANG is
released from RNH1 to freely cleave tRNA (Figure 3b).
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a. Unstressed cells

b. Stressed cells

c. Cancer cells

Figure 3. Angiogenin’s activity is regulated by its cellular localization. (a) In healthy cells, ANG primarily
accumulates in the nucleus to activate transcription and facilitate cell proliferation, while cytoplasmic ANG
is rendered inactive by the tight binding of RNH1. (b) In stressed cells, ANG localizes in the cytoplasm and
dissociates from RNH1 to activate stress responses; nuclear ANG is bound by RNH1 to inactivate
unnecessary transcription activity to conserve cellular resources. (c) In cancer cells, the increased population
of nuclear ANG allows for uncontrolled cell proliferation. Adapted from Lyons et al. 2017.

The activity of cytoplasmic ANG under stress conditions is dependent on the formation
of stress granules.42 Stress granules are cytoplasmic foci that are formed to promote cell survival,
and consist of ribosomal subunits, mRNAs, translation initiation factors and RNA-binding
proteins.43 When localized into stress granules, ANG metabolizes tRNA following two different
mechanisms: (1) reversible cleavage of the CCA overhang of the 3’-termini under mild stress,
and (2) irreversible cleavage of the anticodon loop under more severe stress (Figure 2).
Numerous stress conditions can trigger these mechanisms, including but not limited to oxidative
stress, hypoxia, hypothermia, and nutrition deficiency.44 The cleavage activity of single-stranded
tRNA’s 3’-CCA overhang is reversible and repairable: when cells recover from their stressed
states, a ubiquitous CCA-adding enzyme, TRNT1, proceeds to re-attach the CCA overhang to
the 3’-termini of the tRNA.45 This reversible process allows for dynamic repression and
reactivation of translation in cells, providing metabolic flexibility in response to environmental
stress and suboptimal growth conditions. In contrast, when ANG cleaves the anticodon loop of
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tRNA, two tiRNA halves are irreversible created, rendering the tRNA unusable for translation
purposes.44 The degree of tRNA cleavage is proportional to the concentration of ANG, and
inversely proportional to the concentration of RNH1.46
The ANG-mediated production of tiRNA in the cytoplasm arrests the protein translation
process, sends cells into a survival mechanism, ultimately conserving energy for repair of stressinduced damage.47 In addition, not only do tiRNAs inhibit translation, both tiRNA halves can
promote cell survival by binding to cytochrome C.48 This binding activity between tiRNA and
cytochrome C prevents the formation of apoptosome, an apoptosis-facilitating complex.
Therefore, the production of tiRNA by ANG not only halts protein synthesis to conserve cellular
resources, but also aids in survival of the stressed cells.32
Finally, ANG plays an important role in multiple signaling cascades in the cytoplasm,
such as the SAPK/JNK, ERK1/2, or PI3K/AKT pathways 9 (Figure 2). For instance, the
PI3K/AKT pathway can be activated by an increased concentration of ANG, or suppressed by
the binding of RNH1.49 Upon activation by ANG, these signaling cascades lead to downstream
genetic changes, facilitating for cell growth, survival, proliferation as well as apoptosis.
Transport to the nucleus
The activity of ANG in the nucleus is also critical to cell growth and proliferation. Once
ANG enters the cell, its nuclear localization signal, 31Arg-Arg-Arg-Gly-Lys35 (Figure 1b), directs
ANG to the nucleus and the nucleolus, subsequently, bypassing the cytoplasm.50,51 Hu and
colleagues found that ANG can enter the nucleus within 2 min, reach saturation levels in 15 min,
and remain in the nucleus for 24h.52 This nuclear translocation process (Figure 2) seems to be
independent of microtubule and lysosome,53 and has been observed in proliferative endothelial
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cells,50 cancer cells,54 and neuronal cells.55 The exact mechanistic details of this process still
remain to be elucidated.
Nuclear translocation of ANG is essential to angiogenesis as well as tumor growth. Some
inhibitor molecules, such as neomycin, neamine, or tamoxifen, can target this nuclear
translocation process, and have shown repressive effects towards cellular angiogenesis and tumor
growth in vivo. For example, the angiogenic activity of ANG in human endothelial and umbilical
vein endothelial cells were inhibited upon the introduction of neomycin and neamine.56,57
Additionally, tumor growth of breast cancer tissues and human xenografts were significant
reduced upon treatment of tamoxifen and neamine, respectively.57,58
Ribonucleolytic activity in the nucleus
Under growth conditions, nuclear ANG is not bound by RNH1 (Figure 3) and is free to
perform its catalytic activity—stimulating rRNA synthesis from within the nucleolus (Figure 2).
In endothelial cells, this ANG-mediated rRNA transcription process is essential for angiogenesis,
as co-induced by other angiogenic factors like aFGF, bFGF, VEGF.23 In contrast, in conditions
that don’t favor growth, RNH1 binds to ANG to halt rRNA transcription and conserve anabolic
energy (Figure 3b). In cancer cells, increased rRNA transcription contributes to the uncontrolled
growth and proliferation of those cells52,54 (Figure 3c). Overall, the ribonucleolytic activity of
ANG in the nucleus promotes the generation of ribosomes for protein translation and ultimately
cellular proliferation.59 This stimulatory action of ANG is significant, as ribosomal synthesis is
often the rate-limiting step in protein translation.
To stimulate rRNA transcription, ANG binds to the rDNA in two regions: the
Angiogenin Binding Element (ABE), a CT rich region, as well as the Upstream Core Element
(UCE).60 This binding activity increases the number of actively transcribing rDNAs through
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epigenetic activation. Specifically, ANG binds to histone H3, inhibits the repressive H3K9
methylation, promotes the activating H3K4 methylation process, and activates H4 acetylation at
the rDNA promoter.61 Additionally, ANG can also regulate rRNA synthesis by interacting with
promoter-associated RNA (pRNA). pRNA is a type of non-coding RNA that typically interacts
with the nucleolar remodeling complex (NoRC) to form the pRNA:NoRC complex, which can
silence transcription of pre-rDNA.62 ANG alleviates this silencing action by cleaving pRNA,
therefore preventing the formation of pRNA:NoRC and pre-emptively de-represses rDNA
transcription.63
Perspectives
ANG is a desirable biomolecule to study, given its versatile functions in many cellular
and physiological processes, including cell growth, proliferation, apoptosis, and migration, in
processes as diverse as angiogenesis, tumorigenesis and neurodegeneration. Research at the
molecular level has shown that ANG is involved in enhancing rRNA transcription, mediating
cell stress through the production of tiRNAs, modulating cell migration through protein:protein
interactions, regulating cell proliferation, and much more. However, these growing pieces of
evidence are still somewhat fragmentary, and our current understanding of ANG’s mechanism of
action is far from complete. One way to enrich our current understanding on ANG is by
identifying other ANG-binding proteins, as protein:protein interactions are key modulators of
events in the cellular environment.
At the therapeutic level, a variety of ANG-targeting molecules have been developed to
take advantage of ANG’s clinical potentials. For instance, cancer is an attractive target of ANGtargeting therapies, given ANG’s dual involvement in cancer cell proliferation and tumor
angiogenesis.31 Some published examples of ANG-targeting therapies include anti-ANG
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monoclonal antibodies,64 ANG-binding peptides,65 ANG antisense RNA,66 small molecule
ribonuclease inhibitors,67 neomycin and neamine.56,57,68 Though these molecules have
demonstrated preliminary successes in suppressing ANG in diseased pathways, most of them are
antagonists to ANG itself, and thus can exert significant side effects. In addition, given the high
concentrations of ANG in human serum and its ubiquitous involvement in many processes, ANG
is a difficult biomolecule to target without disrupting its normal physiological functions.
Therefore, in order to further develop ANG-targeting treatments to their full clinical potential, it
is imperative to first obtain a complete picture of ANG’s mechanism of action.
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Split Fluorescence System
Green fluorescent protein (GFP)
In modern day biological research, fluorescent proteins are widely used in the
visualization, quantification, and tracking of structures and processes in living systems. One of
the most common fluorescent proteins used today is the green fluorescent protein (GFP), which
was first identified in 1962 in the bioluminescent jellyfish Aequorea aequorea.69–71 The protein
is encoded by 238 amino acid residues, totaling 26.7kDa in size.69 The well-recognized structure
of GFP is a barrel-like shape of approximately 24 Å in diameter and 42 Å in height, consisting of
11 β-sheets that form the wall of the barrel, and a diagonal α-helical stretch running across the
barrel (Figure 4a).72

a

b

Figure 4. (a) Structure of the Green Fluorescent Protein, with the chromophore from residues Ser-65, Tyr66 and Gly-67 highlighted as orange spheres. (b) The structure of the mature chromophore in GFP.
Structure obtained from PDB code 1GFL and visualized with PyMOL.

GFP is one of the two proteins known for bioluminescence properties in the jellyfish A.
aequorea; the other bioluminescent protein is aequorin. Aequorin undergoes a Ca2+-dependent
chemical reaction to radiate energy in the blue wavelengths.69,70 Blue luminescence emitted by
aequorin is not observed, instead, this energy is transferred to GFP, which then emits photons of
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lower energy in the green wavelengths.73,74 GFP’s most common excitation wavelength is at
488nm, and its corresponding peak emission is at 520nm.75
The fluorescence property of GFP is attributed to a chromophore located in the middle of
the GFP β-barrel.76 This chromophore is produced from a three-step autolytic maturation process
involving three amino acid residues—Ser-65, Tyr-66, and Gly-67.70,75 Unlike the maturation of
aequorin, GFP’s maturation process is independent of cofactor and metal substrate, and only
requires the presence of oxygen.77 The resultant chromophore is a five-membered heterocyclic
structure containing a system of conjugated double bonds (Figure 4b).78,79 GFP’s β-barrel
structure is critical to the formation of this chromophore and thus GFP’s fluorescence properties,
as denatured GFP completely loses its fluorescence.80 The barrel could therefore be thought of as
a protective layer of the chromophore itself.
Today, GFP is used in a remarkable array of biological studies. Some of its key
advantages include the cofactor-independent chromophore formation process, as well as its low
cytotoxicity.72 One of the most common use for GFP is as a fusion tag for protein dynamics
studies, as it can be conveniently added downstream of the gene of interest by molecular cloning
techniques.71,81,82 In most cases, the tagged protein and GFP undergo separate folding
behaviors.83 The GFP tag therefore does not typically affect the localization or activity of the
protein of interest, while many other protein chimeras often experience compromised activity or
misfolding issues. However, despite its numerous advantages, GFP is not perfect. The inclusion
of GFP as a fusion tag faces many challenges, including its somewhat low fluorescence signal,
leading to difficulty in detection in cellular environments with low GFP density, or with high
background fluorescence.72 Therefore, since its discovery, GFP has been subjected to many
rounds of site-directed mutagenesis to optimize its fluorescence properties.75 Many brighter and
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more efficient variants of GFP have been produced since, such as the enhanced GFP84 and
superfolder GFP85 variants.
Split green fluorescent protein
The split green fluorescent protein (GFP) system is an example of how wild-type GFP
was engineered to enhance its versatility in biology.86 In a split GFP system, scientists take
advantage of the deconstructible nature of the peptide bond to splice the protein into smaller
peptide fragments. In particular, the structure of GFP is unique in that all -strands are critical to
its fluorescence activity. The chromophore maturation reaction does not begin if any of the strand is missing, and fluorescence is not observed. Only when GFP fragments reassemble into
the complete can fluorescence be observed.
The most common split GFP system, one that is used in this work, is a bipartite system,
separating the 11th -strand (GFP11) from the rest of the -barrel (GFP1-10) (Figure 5a).87 This
system was originally developed based on the superfolder GFP (sfGFP) molecule, given its
impressive stability.87 The GFP1-10 or the GFP11 fragment alone cannot fluoresce, as the
chromophore is exposed to neighboring water molecules, which can quench the chromophore’s
quantum energy. However, when the GFP1-10 and GFP11 fragments are in close proximity, they
can self-assemble to yield the full -barrel structure. The chromophore activation reaction then
moves to completion, and fluorescence signal is detected (Figure 5b).87 Given these exciting
properties, researchers have spent a lot of effort on optimizing the split GFP reporter technology
for better protein solubility and complementation activity. In particular, the GFP11 tag was
subject to numerous point mutations, and the most optimal construct was reported to contain
three point mutations: L221H, F223Y, T225N.87 The GFP11 peptide sequence used in our work
is RDHMVLHEYVNAAGIT, in which the three amino acid substitutions are underlined.
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a

GFP1-10

b

GFP11

Figure 5. (a) Ribbon diagram of GFP (PDB code 1GFL), with GFP1-10 colored in green, and the 11th βstrand (GFP11) colored in orange. (b) Schematic representation of a bipartite split GFP system. The
protein of interest (POI) is conjugated to the GFP11 tag, and the fusion protein is introduced to the larger
GFP1-10 fragment. Fluorescence is restored when the GFP β-barrel is reassembled from the two
complementary GFP1-10 and GFP11 fragments. Adapted from Pedelacq and Cabantous 2019.

Applications of the split GFP system
The bipartite GFP system offers a flexible platform for scientists to study protein:protein
interactions. In such studies, GFP11 is tagged to the protein of interest by recombinant cloning,
and the larger GFP1-10 reporter portion is similarly attached to other interacting protein(s).
When the two proteins of interest interact with one another, the GFP11 tag can bind to GFP1-10
reporter, thereby restoring fluorescence. The measured fluorescence signal can thus be used to
quantify the extent of protein:protein interactions. The most prominent advantage of this split
GFP system is its versatile and small size of GFP11 (1.8kDa), in contrast to the rather hefty size
(26.7kDa) of wild-type GFP. Additionally, this system typically does not alter the solubility or
the folding of the protein of interest,87 making it an ideal candidate for protein tagging.
For example, Kamiyama and colleagues used split GFP for live cell labelling for
cytoskeletal proteins like actin, clathrin, or histone H2B proteins.88 They also demonstrated the
ability to knock-in GFP11 tags into endogenous proteins via CRISPR-mediated homologydirected repair. Moreover, they developed a tandem system to conjugate the protein of interest to
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multiple fluorescent tags, thereby enhancing the fluorescence signal and alleviating the risks of
photobleaching and phototoxicity.
The split GFP system has also been utilized to visualize the subcellular localization of a
range of proteins. For instance, to discern the ER topology of vaccinia virus proteins, the protein
of interest was fused to GFP11, and cellular sensors were constructed by conjugating GFP1-10 to
a cytoplasmic protein or an ER lumenal protein.89 The dynamics of the mitochondria-mediated
protein degradation pathway was also studied via a split GFP system, where the expression of
GFP1-10 in the mitochondria elucidated the movement of the misfolded protein from the cytosol
into the mitochondria before degradation in the proteosome.90
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Research Design
Motivated by the versatility of these split GFP scaffolds, we developed a split GFP
reporting system to study ANG in human cancer cells. Our work centered around designing a
suite of GFP11-tagged ANG fusion proteins (ANG-GFP11), and characterizing their suitability
for internalization studies on a human cancer cell line containing GFP1-10 (HeLaGFP1-10) (Figure
6). The most optimal ANG-GFP11 protein candidate needs to achieve the following goals: (1) to
retain ANG’s catalytic activity, (2) to enter HeLaGFP1-10 cells by receptor-mediated endocytosis,
and (3) to reconstitute with intracellular GFP1-10 fragment to restore fluorescence.

Figure 6. A schematic overview of ANG-GFP11 fusion protein in internalization studies. ANG-GFP11
protein is introduced to the target HeLaGFP1-10 cell line containing non-fluorescent GFP1-10 reporters.
Upon successful internalization, the GFP11 tag on ANG can bind to GFP1-10 to restore bright green
fluorescence signal.

Six different variants of the ANG-GFP11 fusion protein were developed in our work
(Figure 7a). In the N-terminal variants, GFP11 was conjugated to the amino terminus of ANG,
hereafter referred to as NxAC, where x represented the number of GFP11 tags (1, 2, or 4).
Similarly, three C-terminal variants were developed with GFP11 conjugated to the carboxyl
terminus of ANG, hereafter referred to as NAxC. Though C-terminal tags have shown
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significantly better results than N-terminal tags in previous studies,91 we still wish to explore the
versatility of the split GFP system by experimenting with both N- and C-terminal tags.
a

1xGFP11
N-terminal
tagging
(NxAC)

C-terminal
tagging
(NAxC)

N1AC

NA1C

2xGFP11

4xGFP11

N2AC

N4AC

NA2C

NA4C

b

Figure 7. (a) Design of the six ANG-GFP11 fusion constructs: variants with GFP11 tagged on the Nterminal of ANG are denoted NxAC, and those with GFP11 tagged on the C-terminal of ANG are
denoted NAxC. (b) Each protein moiety in the fusion construct is connected by a Glycine/Serine linker
molecule, denoted (GS)n linker. Shown in this example here is the NA4C variant.

In each fusion variant, a Glycine/Serine-based ((GS)n) linker molecule was used to
connect GFP11 with ANG, or in between tandem GFP11 tags (Figure 7b). The linker provides
flexible linkage between the protein moieties while preserving the biological activity of each
moiety.92,93 In addition, the polar Ser residue can form hydrogen bonds with surrounding water
molecules, therefore reducing unfavorable interactions between the linker and the protein
domains.94 The full amino acid sequences of the six fusion proteins are reported in Appendix 1.
With this suite of ANG-GFP11 fusion proteins, we set out to identify the most promising variant
that satisfies our design goals as mentioned above.
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MATERIALS & METHODS
Structure predictions and visualization
The three-dimensional structures of the six ANG-GFP11 fusion proteins were predicted
using the Robetta server95 at http://robetta.bakerlab.org/. Amino acid sequences of each fusion
protein (Appendix 1) were inputted into the server. The structures of ANG (PDB code 1B1I) or
GFP (PDB code 1GFL) were used as templates for the 3D structure predictions. PDB files
generated from the server were visualized in PyMOL. Homology alignment was also carried out
in PyMOL for the fusion proteins and wild-type ANG (PDB code 1B1I), using the “align”
command. Images were exported as PNG files.
Theoretical predictions of protein thermal stability
Using the resultant PDB files from the Robetta server, the thermal stability data of each
fusion protein was predicted using the SCooP server96 at http://babylone.ulb.ac.be/SCooP. The
protein’s melting temperature, Tm, and the Gibbs free energy, ∆Gf, were calculated therein.
Cloning of ANG-GFP11 variants
The fusion proteins were constructed using Gibson Assembly cloning on a pET-22b
vector, using NEBuilder reagents (Figure 8). Two Geneblocks for 4xGFP11-ANG and ANG4xGFP11 (Integrated DNA Technologies) were previously designed by Dion-Kirschner,97 each
containing the genetic code for four GFP11 tags and ANG in the corresponding orientation.
Gibson primers were designed to bind to the Geneblocks as well as the pET-22b vector
backbone, amplifying the appropriate region with 16-42 base-pair overlaps (Appendix 2). The
inserts for all N-terminal proteins (NxAC) were amplified from the 4xGFP11-ANG Geneblock,
and those for C-terminal proteins (NAxC) were amplified from the ANG-4xGFP11 Geneblock.
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Figure 8. Schematic representation of the cloning process for ANG-GFP11 fusion proteins. The work shown
here is for NAxC proteins from the ANG-4xGFP11 Geneblock, and the exact same workflow would be
carried out for NxAC proteins from the 4xGFP11-ANG Geneblock. The pET-22b vector and Geneblocks
are amplified via PCR with the appropriate primers (Appendix 2). The amplified insert and vector are
then recombined for Gibson Assembly to yield a fully ligated vector, which is then transformed into E. coli
DH5α cells for protein expression purposes.

The workflow of Gibson Assembly and transformation of ANG-GFP11 fusion proteins is
outlined in Figure 8. The pET-22b vector was digested with XhoI and NdeI enzymes in
CutSmart Buffer (New England Biolabs), which was then PCR-amplified using primers #1, 2
(Appendix 2) with Q5 polymerase (New England Biolabs). The six ANG-GFP11 inserts were
PCR-amplified from the appropriate Geneblock and Gibson primers (Primers #3-10, Geneblocks
#17, 18, Appendix 2) using Q5 polymerase (New England Biolabs), followed by gel purification
(Qiagen QIAquick Gel Extraction Kit). Gibson Assembly was individually carried out for each
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of the six inserts into the vector backbone. The fully ligated vector containing the fusion gene of
interest was then transformed into chemically competent DH5α E. coli cells (New England
Biolabs) and plated on LB+Amp plates (100mg/mL).
Colonies were screened by PCR with the appropriate T7 primers (#11, 12, Appendix 2)
and resolved by gel electrophoresis with 1% agarose gel. Successful hits were then expressed in
Terrific Broth liquid cultures (containing 100µg/mL carbenicillin) and miniprepped for Sanger
sequencing using sequencing primers (#13-16, Appendix 2), carried out at either Yale’s DNA
Analysis Facility on Science Hill (New Haven, CT) or at ELIM Biopharmaceuticals (San
Francisco, CA). Sequencing results were confirmed by alignment using Benchling.com.
Protein expression and purification
ANG-GFP11 plasmids with the correct sequencing alignments were transformed in BL21
(DE3) E. coli cells (Lucigen) and plated on LB agar plates (containing 100µg/mL ampicillin),
following standard chemical transformation protocols. Colonies were picked and inoculated into
25mL of Luria Broth (containing 50µg/mL carbenicillin), then shaken at 37°C for 4-5h until
cloudy. 8mL of this starting culture was inoculated into 1L of Terrific Broth containing 50µg/mL
carbenicillin in 2.8L Fernbach flasks, grown shaking at 280rpm at 37°C until OD600 reaches 1.5.
OD600 values were measured using Cary50 instrument and the SimpleReads software. Cells in
this liquid culture were then induced with IPTG to a final concentration of 1.0mM (BioBasic)
and grown for an additional 3.5h. Cells were collected by centrifugation at 5,000xg for 15 min,
then resuspended in 10mL of lysis buffer (20mM Tris-HCl pH 8.0, 10mM EDTA) per 1L of
culture. Cell suspension was stored at -80°C until further needed.
After the frozen cell suspension was thawed, lysozyme (Amresco, or MedChem Express)
was added to a final concentration of 10mg/mL, and the suspension was incubated for 1 hour in
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an ice-cold water bath. Cells were lysed by sonication (Branson Digital Sonifer) with five 3-min
intervals at 30% power. The lysed cells were centrifuged at 20,000xg for 45 min, then the pellet
was generously washed with lysis buffer and centrifuged again at 20,000xg for 15 min. The
resulting pellet was primarily comprised of ANG inclusion bodies, which were either stored at 80°C or denatured immediately.
Inclusion bodies from 1.0L of liquid culture were denatured in 15mL of denaturing
solution (20mM Tris-HCl pH 7.0, 7M Guanidine-HCl, 10mM EDTA), then transferred to a
250mL Erlenmeyer flask. Fresh dithiothreitol (DTT) was added to this protein solution to a final
concentration of 0.1M, then the solution was stirred gently for 3-4h at room temperature until the
solution was homogenous. The solution was then slowly diluted using a syringe fitted stopcock
with 200mL of 20mM acetic acid, then centrifuged at 16,000xg for 30 min to remove any
precipitate. The supernatant was collected and transferred to Spectra/por3 3,500 MWCO dialysis
tubing (Repligen). Dialysis was carried out overnight at 4°C against 12L of 20mM acetic acid.
The contents of the dialysis bag were centrifuged at 16,000xg for 30 min to remove
precipitate. Refolding was carried out by adding the supernatant dropwise into 1.0L of refolding
buffer (10mM Tris-HCl pH 7.6, 100mM NaCl, 0.5M Arginine, 10mM EDTA, 1.0mM reduced
glutathione, 0.2mM of oxidized glutathione) per 1.0L of liquid culture. Refolding was allowed to
proceed over the course of 2-3 days at 4°C with no stirring.
The pH of refolded protein solution was adjusted to 5.0 with glacial acetic acid, and
refolded protein was concentrated using Vivaspin 20 5K MWCO column (BioExpress) or a
HiTrap SP column (GE Healthcare Life Sciences). If a HiTrap SP column was used, the column
was generously equilibrated with Buffer A (A (50mM NaOAc pH 5.0, 10mM EDTA). Then, the
refolded protein solution was diluted in 1:1 ratio with 1.0L of Buffer A prior to loading. After all
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of the dilute protein was loaded through the column, the column was washed with 2 column
volumes of Buffer A; then, the protein was eluted with 10mL Buffer B (50mM NaOAc pH 5.0,
10mM EDTA, 1M NaCl).
No more than 10mL of this concentrated protein solution was then loaded on a Superdex
G75 Gel Filtration column (dimensions 2.6cm x 60cm, GE Healthcare Life Sciences), which had
been pre-equilibrated with filtration buffer (0.05M NaOAc pH 5.0, 0.1M NaCl, 0.025M NaN 3).
An additional ion exchange purification step was carried out for unresolved FPLC fractions
using a HiTrap SP cation-exchange column (GE Healthcare Life Sciences). The fractions
corresponding to monomeric ANG with GFP11 tags (17-23kDa) were pooled, dialyzed and
stored in 1xPBS at 4°C for further experiments. Protein concentrations were determined by UV
spectroscopy at 280nm using extinction coefficients determined theoretically by Benchling.com.
SDS-PAGE analysis was conducted on cell lysates before and after IPTG induction,
refolded protein solution, and purified protein solution. Approximately 20µg of protein of each
sample was mixed with 5x sample buffer (250mM Tris-HCl, pH 6.8, 10% SDS, 30% v/v
glycerol, 10mM DTT, 0.05% w/v bromophenol blue, heated at 70°C for 15 min, vortexed,
centrifuged at 10,000rpm for 30s, then loaded onto each lane of a precast 4-20% MiniPROTEAN polyacrylamide gel (BioRad). A standard molecular weight ladder PrecisionPlus
Protein Marker (BioRad) was also loaded. The gel was run at 120V in a Mini-PROTEAN Tetra
system (BioRad) with 1x Tris/Glycine/SDS Running buffer (25mM Tris, 192mM glycine, 0.1%
SDS) for 45 min. Gels were stained with Coomassie blue solution, heated in the microwave for
45s, and incubated rocking at room temperature for 1h. Gels were destained with a 40% EtOH
and 10% acetic acid solution, heated in the microwave for 45s and incubated rocking at room
temperature for at least 2h before being imaged.
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Ribonucleolytic activity of ANG-GFP11 fusion proteins
To determine the ribonucleolytic activity of ANG variants, a fluorescence-based assay
was used. The fluorogenic RNaseAlert substrate (Integrated DNA Technologies) is a
fluorescence-quenching oligonucleotide probe that can emit fluorescence after being cleaved by
ribonucleases, such as ANG (Figure 9). Therefore, it can be appropriately adapted to study the
ribonucleolytic activity of ANG-GFP11 fusion proteins.

Figure 9. The fluorogenic RNA substrate links a reporter molecule (R) and a
quencher molecule (Q). When the RNA substrate is uncleaved, Q quenches all
excitation energy around the 490nm wavelength, and no fluorescence is detected.
When the substrate is cleaved by ANG or any other RNase, R is released from Q.
The fluorescence properties of R are restored—R can now absorb energy at
490nm and emit signal at 520nm.

In each well of a 96-well microplate, 10µL of 10x sample buffer was mixed with 80µL of
ANG protein (wild type, NA1C, NA2C, or NA4C) to yield a final 3.0µM protein concentration.
Catalysis was initiated with the addition of 10µL of the fluorogenic substrate. The fluorescence
intensity of each reaction (485nm excitation and 520nm emission) was measured at regular
intervals (every 2 min for t<50min, then every 10 min thereafter) using POLARstar Omega plate
reader (BMG Labtech) and Omega software. A negative control was included, where 80µL of
nuclease-free water was added in place of ANG. The fluorescence signal of this negative control
well was subtracted from those of the sample wells. For data analysis, the final level of
fluorescence was normalized across all protein samples.
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Tissue culture maintenance
The target cell line used in this study is HeLa SFFV dCas9-KRAB GFP1-10 (HeLaGFP110),

as prepared in the Weissman Lab (UC San Francisco, CA). This is a human cancer cervical

cell line in which the GFP1-10 fragment is stably expressed under a spleen focus forming virus
(SFFV) promoter.
Cells were grown in 10cm dishes (VWR) under standard tissue culture conditions—at
37°C and 5% CO2 (g) in a humidified incubator. Cells were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) (Gibco, Thermo Fisher Scientific), 10% v/v fetal bovine serum (FBS)
(Gibco, Thermo Fisher Scientific) and 5% v/v penicillin-streptomycin-glutamate solution (PSG)
(Gibco, Thermo Fisher Scientific). Cells were harvested by trypsinization with 0.25% TrypsinEDTA (Sigma Aldrich), incubated at 37°C until detached, neutralized with equal volumes of
DMEM media, then centrifuged at 5,000rpm for 5 min.
Characterization of GFP1-10 expression in fractionated HeLaGFP1-10 cells
The distribution of GFP1-10 in the target HeLaGFP1-10 cell line was established by western
blotting. Cells were grown to 80% confluency in ten 10cm dishes, then harvested by
trypsinization as described above. Cell pellets were washed generously thrice with 5mL of icecold PBS, then resuspended in 5mL of a 10mM Hepes buffer pH 7.9, containing 10mM KCl,
1.5mM MgCl2, 0.5mM DTT and 10% protease inhibitor (Thermo Scientific). The cell
suspension was incubated on ice for 5 min, then transferred to a Dounce homogenizer and
homogenized on ice for 100 strokes, until more than 90% of cells were burst. This homogenized
cell mixture was centrifuged at 2,000rpm for 5 min at 4°C, after which the supernatant was
collected as the cytoplasmic fraction. The nuclear pellet was washed twice with PBS, then
resuspended in 3mL of a 0.25mM sucrose solution, containing 10mM MgCl2 and 10% (v/v)
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protease inhibitor (Thermo Scientific). This solution was overlaid on a sucrose gradient
containing 3mL of 0.35mM sucrose solution, containing 0.5mM MgCl2 and 10% protease
inhibitor (Thermo Scientific), and centrifuged at 2,500rpm for 8 min at 4°C. The pellet was once
again resuspended in 3mL of the above 0.35mM sucrose solution, then sonicated in six 10s
ON/30s OFF increments to retrieve the nuclear proteins. Both the cytoplasmic and nuclear
fractions were aliquoted and stored at -80°C until further needed.
The protein concentration of each fraction was measured, then approximately 20µg of
protein from each fraction was mixed with 5x sample buffer (250mM Tris-HCl, pH 6.8, 10%
SDS, 30% v/v glycerol, 10mM DTT, 0.05% w/v bromophenol blue), heated at 70°C for 15 min,
vortexed, centrifuged at 10,000rpm for 30s, and the supernatant loaded onto each lane of a
precast 4-20% Mini-PROTEAN polyacrylamide gel (BioRad). The gel was run at 120V in a
Mini-PROTEAN Tetra system (BioRad) with 1x Tris/Glycine/SDS Running buffer (25mM Tris,
192mM glycine, 0.1% SDS) for 45 min. The gel was transferred to an Immobilon-P PVDF
membrane (Sigma-Aldrich) at 100V for 1h. After transfer, the membrane was blocked with
blocking buffer (5% w/v milk in TBS-T) for 2h at room temperature, or overnight at 4°C.
Western blot membranes were probed for cytoplasmic or nuclear markers, using rabbit
anti-α-tubulin or rabbit anti-KDM1 antibodies (BosterBio), respectively. The antibody solutions
were diluted to 0.5µg/mL concentration in blocking buffer and incubated with the blot overnight
at 4°C. Then, membranes were washed thrice in TBS-T for 5 min each, before incubation with
0.5µg/ml anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Dallas, TX) in blocking buffer for 1
hour at room temperature. After incubation with the secondary antibody, membranes were
washed thrice in TBS-T for 5 min each and visualized with SuperSignal™ West Femto
Maximum Sensitivity Substrate or SuperSignal™ West Pico Maximum Sensitivity Substrate
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(ThermoFisher Scientific). 10mL of the Femto stain’s working solution was mixed with 250µL
of the Pico stain’s working solution, in which the membrane was incubated for 4 min before
being imaged. Imaging was carried out using UVP imaging software.
In order to detect GFP in the nuclear and cytoplasmic fractions, the membranes were
stripped twice with a mild stripping buffer (200mM glycine, 0.1% SDS, 1% Tween20, pH 2.2),
then washed generously twice with PBS and TBST before re-blocking. Incubation with antibody
solutions and visualization were repeated similarly to above, with 0.8µg/mL mouse anti-GFP
(Sigma Aldrich) as the primary antibody and 20ng/mL donkey anti-mouse IgG-HRP (Santa Cruz
Biotechnology) as secondary antibody.
In vitro GFP reconstitution
An important proof-of-principle experiment was the in vitro reconstitution of GFP, in
which HeLaGFP1-10 cell lysates were mixed with ANG-GFP11 fusion proteins in a 96-well
microplate. The microplate was blocked with 0.5% BSA (w/v) solution in TNG buffer (50mM
Tris-HCl, pH 7.4, 100mM NaCl, 10% glycerol) overnight at 4°C. HeLaGFP1-10 cell lysates were
prepared from confluent dishes of cells grown at standard tissue culture conditions. Harvested
cells were resuspended in a 10mM Hepes buffer at pH 7.9, containing 10mM KCl, 1.5mM
MgCl2, 0.5mM DTT and 10% protease inhibitor (Thermo Scientific). The cell lysates were
serially diluted to four concentrations (1:1, 1:2, 1:4, 1:8) in TNG buffer (50mM Tris, pH 7.4,
0.1M NaCl, 10% (v/v) glycerol), and 50µL of each lysate fraction was added to each well.
100µL of 0.6mg/mL of the wild-type ANG (wt-ANG) or the fusion proteins were subsequently
added to each well. To correct for background fluorescence of the cell lysates, negative controls
were included, containing 50µL of each cell lysate concentration and 100µL of PBS in place of
the protein. Samples were incubated at 37°C for 30 min, then slowly cooled to room temperature
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over 1h. Fluorescence was measured (485nm excitation and 520nm emission) with a POLARstar
Omega plate reader (BMG Labtech) and Omega software. For data analysis, background
fluorescence signals from the negative control wells were subtracted from those of the incubated
protein samples.
Cellular internalization studies
The uptake of ANG-GFP11 fusion proteins by HeLaGFP1-10 cells was evaluated using flow
cytometry. Cells were grown in 6-well plates (Corning Inc.) under standard tissue culture
conditions until 70% confluency, then serum-starved for 24h prior to incubation with the fusion
proteins. ANG-GFP11 fusion proteins were incubated with the HeLaGFP1-10 cells for 2h at 5µM
concentration in serum-free media. The negative control of this experiment was HeLaGFP1-10 cells
grown under identical conditions, but were not incubated with ANG-GFP11 fusion proteins.
Cells from each well were harvested by trypsinization and centrifugation at 1,500rpm for 6 min,
then resuspended in 1mL of ice-cold PBS and transferred to FACS tubes.
For flow cytometry experiments, GFP signal was detected with BD FACSCalibur Flow
Cytometer at FL1 (530nm) and CellQuest Pro software. The average fluorescence reading of
10,000 cells was measured for each run. Statistical significance of the obtained data was
determined by p tests performed in Microsoft Excel.
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RESULTS
Structure predictions of ANG-GFP11 fusion proteins
Three-dimensional structures of the ANG-GFP11 proteins, as guided by ANG’s crystal
structure (PDB code 1B1I), are reported in Figure 10. The resulting protein structures showed
good alignment with ANG (match score ranging between 0.257 and 0.367, with 0 being perfect
alignment; data not shown). This suggested that the addition of GFP11 tags likely did not
interfere with the native structure of ANG. In addition, the predicted GFP11 tags (in green) were
on the periphery of the structure of ANG (in red) and did not block its active site. However, the
GFP11 portions of the fusion protein were predicted to be in α-helical form, as opposed to the
expected β-sheets. β-sheet structures are imperative for GFP11 to reconstitute with GFP1-10 and
restore fluorescence.
1xGFP11

2xGFP11

4xGFP11

N1AC

N2AC

N4AC

NA1C

NA2C

NA4C

N-terminal
tagging (NxAC)

C-terminal
tagging (NAxC)

Figure 10. Structure predictions of the six ANG-GFP11 fusion proteins, created via the Robetta server
with ANG as a template (PDB code 1B1I), and visualized using PyMOL. The ANG portions are colored
in red, and the GFP11 portions are colored in green.
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In an attempt to remedy the inappropriate structure of GFP11, the crystal structure of
GFP (PDB code 1GFL) was used as a template to guide the structure prediction algorithms for
NA1C. This returned a PDB structure with the correct β-sheet formation for GFP11 (Figure 11a).
However, the ANG portion was pitifully misaligned compared to the PDB structure of ANG
(Figure 11b), as shown through a match score of 18.473 (data not shown). This score was much
higher compared to that of the ANG-modelled structure, suggesting that the GFP-modelled
structure failed to retain the correct crystal structure of ANG. It is also worth noting that the
GFP11 strand is buried within the ANG structure, rendering it less accessible for interactions
with GFP1-10 (Figure 11c).

a

b

c

Figure 11. (a) Predicted structure of NA1C, modelled from GFP (PDB code 1GFL). ANG wass colored
in red and GFP11 in green. (b) Homology alignment of wild-type ANG (colored in mauve) and
predicted NA1C structure (red/green). (c) Mesh/ribbon structure of the NA1C variant. Structures were
obtained from the Robetta webserver and visualized using PyMOL.
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Theoretical predictions of protein thermal stability
Table 1 reports theoretical data for the thermal stability of wt-ANG and ANG-GFP11
fusion proteins. The melting point (Tm) of wt-ANG was calculated to be 65.1°C, a 2.8%
overestimate compared to experimental values.17 The estimated Tm values for the fusion proteins
were on average 3.8% lower than that of wt-ANG, varying between 60.9°C and 64.5°C. The
Gibbs energy of folding (∆Gf) of the fusion proteins were not as drastically modified, resulting in
only an average 0.20% decrease compared to wt-ANG.
The thermal stability of N-terminal fusion proteins seemed to slightly differ from their Cterminal counterparts. For the N-terminal fusion proteins, longer GFP11 tags led to lower Tm
values, implying a destabilizing effect of the GFP11 tags. For the C-terminal fusion proteins, the
destabilizing effect is less obvious with no apparent trend in how the size of the GFP11 tag
influenced the fusion protein’s thermal stability.
Table 1. Theoretical thermal stability data of wt-ANG and ANG-GFP11 fusion proteins. Melting
temperatures, Tm, are reported in °C, and Gibbs free energy of folding, ∆Gf, are reported in kcal/mol.
All data obtained theoretically from SCooP server based on modelled PDB structures.
Melting temperature, Tm; (Gibbs free energy, ∆Gf)
wt-ANG
Fusion ANG

65.1°C (-8.2kcal/mol)
N-terminal

C-terminal

1x 64.5°C (-8.9kcal/mol)

64.0°C (-8.4kcal/mol)

2x 63.6°C (-8.7kcal/mol)

61.1°C (-7.8kcal/mol)

4x 60.9°C (-7.9kcal/mol)

61.8°C (-7.6kcal/mol)
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Cloning, expression and purification of ANG-GFP11 fusion proteins
The six ANG-GFP11 fusion protein variants were successfully cloned by Gibson
Assembly and transformed into E. coli DH5α cells. Table 2 reports the corresponding size of
each variant, and our colony screening result showed the correct fragment size for all six fusion
variants (Figure 12).
Table 2. Expected size of ANG-GFP11 inserts, following PCR amplification with T7 primers.
Fusion protein

N-terminal

C-terminal

Size (bp)

N1AC

617

N2AC

680

N4AC

806

NA1C

629

NA2C

692

NA4C

803

500 bp

N-terminal

C-terminal

Figure 12. Agarose gel electrophoresis of the six ANG-GFP11 variants, following PCR amplification with
T7 primers. The size of each band is reported in Table 2. NxAC: N-terminal GFP11-tagged ANG, NAxC:
C-terminal GFP11-tagged ANG; x: number of GFP11 tags.

Upon confirmation of sequencing results on these ANG-GFP11 plasmids, protein
expression in E. coli BL21 (DE3) and purification were carried out. Subsequent SDS-PAGE
analyses showed that the N1AC fusion protein was not present in cell lysates after IPTG
induction (Figure 13), indicated by the absence of a substantial protein band at approximately
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16.7kDa. On the other hand, all C-terminal fusion proteins, NA1C, NA2C and NA4C,
demonstrated strong expression upon IPTG induction (Figure 13). The inclusion bodies of all
NAxC proteins were isolated, and the component proteins were reduced, denatured, refolded,
and purified to yield pure fractions (Figure 13). The remainder of this work focused on
characterizing these NAxC proteins.

MW
(kDa)

N1AC

NA1C

NA2C

NA4C

25015010075-

503725201510—

+

—

+

D

R

F

—

+

D

R

—

+

D

R

Figure 13. SDS-PAGE analyses of E. coli lysates containing the crude protein, or purifying fractions of the
N1AC protein (panel 1), NA1C (panel 2), NA2C (panel 3), and NA4C (panel 4). Cell lysates were
collected immediately prior to the addition of IPTG (—) or 4h after the addition of IPTG (+). Protein
fractions were collected after dialysis (D), refolding (R), and FPLC purification (F). NA1C and N1AC
migrates as a 16.7kDa band, NA2C and NA4C migrate as a 18.8kDa and 22.7kDa, respectively.
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Ribonucleolytic activity of NAxC fusion proteins
A critical checkpoint in this work is to demonstrate that ribonucleolytic activity of ANG
was conserved in the NAxC fusion variants. The ribonucleolytic activities of wt-ANG and
NAxC were evaluated by the fluorescence signal emitted from a fluorogenic RNA substrate
(Figure 9). wt-ANG, our positive control, completely cleaved the RNA substrate in 50 min, as
fluorescence signal plateaued from 50 min onwards (Figure 14). All NAxC proteins showed
promising ribonucleolytic activity, with NA1C demonstrating the highest activity, followed
closely by NA2C and NA4C. However, these activities were approximately 3-4-fold less
efficient than wt-ANG, as all fusion proteins took more than 100 min to completely cleave the
substrate (Figure 14).

Figure 14. In vitro characterization of the ribonucleolytic activities of wt-ANG and three NAxC fusion
proteins. Time-based activity curves of 1.5µM of wt-ANG (red crosses) or NAxC (various green markers)
were constructed from emitted fluorescence (485nm excitation and 520nm emission) from an RNA
substrate, measured between t=0-240 min. Maximum fluorescence was normalized to 222,000 a.u. n=1.
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Characterization of intracellular GFP1-10 distribution in the target cell line
ANG is known to localize to both the nucleus and the cytoplasm, depending on the cell’s
conditions. In healthy cells, ANG accumulates in the nucleus; in stressed conditions, ANG
localizes to the cytoplasm. Within the scope of this work, we are interested in studying the
intracellular distribution of ANG in cells experiencing different conditions; therefore, it was
imperative to show that GFP was present in both the cytoplasmic and nuclear fractions of our
target cell line. We demonstrated via western blotting that GFP was present in both the nucleus
and cytosol of our target cell line HeLaGFP1-10 (Figure 15). This experiment indicates that our cell
line is suitable for studies of ANG activity under both growth and stressed conditions.

Figure 15. Western blot of nuclear and cytoplasmic fractions of the HeLaGFP1-10
target cell line. KDM1 was used as nuclear marker and α-tubulin as cytoplasmic
marker. GFP was probed on the same blot to detect for GFP presence in both the
nuclear and cytoplasmic fractions.
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In vitro GFP reconstitution
We examined the efficiency of GFP reconstitution in vitro by mixing HeLaGFP1-10 cell
lysate with the fusion proteins. All three NAxC proteins demonstrated approximately a 3-fold
fluorescence increase when mixed with the HeLaGFP1-10 lysate in a 2:1 ratio (Figure 16a). The
NA4C protein showed the highest increase in fluorescence, a 17% increase compared to NA1C,
which was in turn 8% higher than NA2C. Additionally, all three fusion proteins showed a
linearly positive relationship with the percent of HeLaGFP1-10 lysate present (Figure 16b). This
experiment demonstrated that the fusion GFP11 tags can bind to GFP1-10 reporters to restore
GFP fluorescence, and thus laid the foundation for subsequent flow cytometry experiments.
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Figure 16. In vitro restoration of GFP signal. (a) Fluorescence signal of HeLaGFP1-10 cell lysate mixed with
water (grey), wt-ANG (red) or NAxC fusion proteins (green) in a 1:2 ratio. (b) Fluorescence signal of
varying amount of HeLaGFP1-10 cell lysate incubated with water (grey), wt-ANG (red), or the fusion proteins
(green). Samples were incubated at 37°C for 30 min., then slow-cooled to room temperature, at which
point fluorescence signal (485nm excitation, 520nm emission) was measured. n=1.
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Quantifying NAxC’s cellular internalization capacity
Flow cytometry was used to measure the degree of internalization of NAxC fusion
proteins by the target HeLaGFP1-10 cell line. Fluorescence signals of cells treated with NAxC
proteins, relative to untreated cells, reflects the degree of protein internalization. If NAxC
proteins enter cells successfully, the GFP11 tag can reconstitute with the GFP1-10 reporter in the
cells and restore fluorescence signal.
Our flow cytometry analyses revealed that the NA1C protein was not internalized by
HeLaGFP1-10 cells, as the treated cells exhibited a 30% lower fluorescence signal than that of the
untreated cells (Figure 17a). The NA4C-treated cells exhibited a higher fluorescence signal than
that of the untreated cells, though not statistically significant (Figure 17b). At the same time, this
signal was lower than that for the wt-ANG treatment group (Figure 17b). The wt-ANG treatment
was a negative control, and thus should have shown comparable base-line fluorescence to the
untreated cells. Therefore, taken together, our data was inconclusive as to whether the NA4C
treatment group was successfully internalized by our target cells.
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Figure 17. Flow cytometry on HeLaGFP1-10 cells incubated with (a) the NA1C protein, and (b) the NA4C
protein. Cells were either left untreated, treated with 5µM wt-ANG as a negative control, or with 5µM of
the corresponding fusion protein. 10,000 cells were counted for each reading. Fluorescence was measured
with FL1 channel on BD FACSCalibur Flow Cytometer at 530nm emission wavelength. Error bars represent
standard deviation; n=3.
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DISCUSSION
ANG is a multi-functional protein that holds important roles in cell growth and survival
of many different cell types. At the same time, due to ANG’s complex biological involvements,
it has been rather challenging to elucidate the complete mechanism of action of ANG.
Particularly, one of the most pressing research questions is the uptake of ANG in cells
experiencing stress, such as cancer cells. It is therefore imperative to develop a unique reporting
system to study ANG in these special cellular environments. In this work, we adopted the splitGFP technology to create ANG-GFP11 fusion proteins and investigated their compatibility with
cell internalization studies on HeLaGFP1-10 cells.
Our research design consists of six ANG-GFP11 proteins, including variants with GFP11
(1x, 2x, or 4x) tagged to either N-terminus and C-terminus of ANG. Introducing additional
amino acids to a protein can disrupt its folding and impair its normal function, even with a
relatively small fusion tag such as GFP11. In this work, we were especially concerned about the
folding of the fusion proteins, as the addition of GFP11 could block access to ANG’s active site
or interfere with its substrate binding capacity. We therefore designed a diverse suite of fusion
proteins with the intention to identify at least one functional variant. We expected that the
variants with 4xGFP11 would provide the highest change in fluorescence, up to 4 times,98 as
multiple units of GFP1-10 can assemble on an extended GFP11 tail. However, the bulky
4xGFP11 tail might block the active site of ANG or hinder its internalization into cells. On the
other end of the spectrum, the small 1xGFP11 tag might return modest fluorescence activity, but
is minimally disruptive to ANG. With these hypothesized pros and cons in mind, we set out to
identify the most optimal fusion protein that satisfies the following goals: (1) to retain ANG’s
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catalytic activity, (2) to enter HeLaGFP1-10 cells by receptor-mediated endocytosis, and (3) to
reconstitute with intracellular GFP1-10 fragment to restore fluorescence.
Theoretical predictions of protein structure and thermal stability
We obtained two sets of structure prediction data for ANG-GFP11 fusion proteins, as
guided by the crystal structure of either GFP or ANG. In the GFP-guided structure, GFP11 took
shape of a β-sheet; however, the ANG portion was severely misfolded (Figure 11). The fusion
protein would lose ANG’s native activity if it were to fold this way. In contrast, the ANG-guided
structure showed that ANG folded into the correct tertiary structure, and GFP11 did not obstruct
ANG’s active site (Figure 10). However, the predicted GFP11 portions lost their β-sheet
structure and instead took shape of α-helices (Figure 10).
We gathered three lines of evidence to suggest that the ANG-guided structure was likely
more accurate. First, the ANG proportion made up the majority of the fusion protein and
therefore is better suited as a template for prediction algorithms. Second, our RNA cleavage
assay showed that all C-terminal fusion proteins retained ribonucleolytic activity (Figure 14),
indicating that the ANG portion must have been folded properly in order to retain its activity.
Third, the alpha-helical form of GFP11 might not necessarily preclude it from interacting with
GFP1-10, as the surrounding environment can force GFP11 to adopt the correct beta-sheet
conformation. The transition between alpha-helix to beta-sheet is a universal deformation
mechanism that has been observed in various proteins, given the right chemical environment.99
Specifically, beta sheets are formed only when the peptide chain can establish stabilizing
hydrogen bonds with neighboring amino acid residues. GFP11 will likely undergo
conformational changes upon interacting with GFP1-10, morphing into a beta sheet that is
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stabilized by hydrogen bonds with the GFP1-10. Indeed, our in vitro reconstitution assay showed
that GFP signal was successfully restored from the GFP1-10 and GFP11 fragments (Figure 16).
The predicted thermal stability of ANG-GFP11 fusion proteins also indicated that ANG
maintains structural integrity in the presence of GFP11 tags. The estimated values for melting
temperatures and Gibbs free energy of folding indicated that our fusion proteins might be slightly
destabilized compared to wt-ANG (Table 1), and the destabilizing effect can be attributed to the
addition of the negatively charged GFP11 tag(s). We must acknowledge that these sets of
theoretical data might be prone to miscalculations and algorithm biases; however, taken
altogether, this theoretical our models suggest that the fusion proteins can be functionally and
stably expressed.
Protein expression and activity
C-terminal GFP11 tagging has demonstrated better success for protein expression on the
E. coli BL21 (DE3) system (Figure 13), as consistent with previous literature.94 In contrast, the
N-terminal 1xGFP11 variant, N1AC, repeatedly failed to express. Other N-terminal variants
have not been expressed yet, as we focused our experiments on the C-terminal variants due to
time constraints. Future studies can attempt to express these three N-terminal variants in an
enhanced E. coli system, such as Rosetta (DE3), to complete the repertoire of fusion proteins for
downstream studies.
Following successful expression and purification, we showed that all three NAxC
proteins exhibited robust cleavage activity towards RNA substrates, though 3- or 4- fold less
efficient compared to wt-ANG. This result suggested that although the catalytic activity of ANG
was largely conserved, the GFP11 tags might have partially obstructed the substrate binding site
and thus impaired catalysis. Dose-response catalytic activities of wt-ANG and NAxC proteins
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are also reported in Appendix 3. We acknowledge that the conditions of this assay were
suboptimal. First, the assay was adapted from a fluorimeter to a microplate reader, hence
compromising temporal and signal sensitivity. Second, the generic RNA substrate used was not
optimized for ANG as well as the structural limitations of its active site. Due to these suboptimal
experimental conditions, the kinetic profiles of our fusion proteins reported herein are
qualitative. More replicates should be carried out in the future with a fluorimeter and an ANGspecific RNA substrate to verify this preliminary data.
Cell-based studies
Prior to conducting cell-based studies, we showed that GFP1-10 is strongly expressed in
the HeLaGFP1-10 cell line (Figure 15), and the cell line therefore is suitable for use in our split
GFP detection system. However, the level of GFP presence could not be quantitatively
determined due to impure cell fractionation. Though the cytoplasmic fraction was pure, the
nuclear fraction was not, as shown in the detection of cytoplasmic α-tubulin in both fractions
(Figure 15). This was likely due to an imperfect cellular fractionation protocol, where soluble
cytoplasmic extracts were still present, even after multiple washes. Future work can attempt to
quantitatively characterize the GFP1-10 distribution with purer cellular fractionation.
We demonstrated successful restoration of GFP fluorescence upon the combination of the
NAxC proteins and HeLaGFP1-10 cell lysate, resulting in a 3-fold increase of fluorescence signal
(Figure 16a). It was intriguing that the NA4C variant, with four tandem GFP11 tags, did not
return a significantly higher fluorescence reading compared to NA1C. Unfortunately, no
statistical significance could be derived from this experiment due to the lack of replicates, and
future work should attempt to reproduce this result with more replicates. Regardless, this key
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result showed that fluorescence signal could be used to quantify the degree of protein
internalization in HeLaGFP1-10 cells.
Finally, disappointing flow cytometry analyses showed that neither NA1C nor NA4C
were internalized into HeLaGFP1-10 cells (Figure 17), or the restored GFP signal might have been
below the instrument’s limit of detection. It is possible that the flow cytometer failed to detect a
GFP signal, as it had not been properly calibrated. In a control experiment where HeLaGFP1-10
cells were transfected with a plasmid driving high levels of GFP expression, the instrument
failed to detect GFP fluorescence in most cells (data not shown). Therefore, our flow cytometer
might not be functional and well-suited for this study.
Equipment issues are not the only explanation for our inability to detect uptake of our
fusion proteins. The incubation period of 2h might not have been long enough for fusion ANG to
be internalized by receptor-mediated endocytosis. Furthermore, and perhaps most importantly,
the GFP11 tag might have interfered with the cellular internalization of ANG. The GFP11 tag
carries a strong negative charge with an isoelectric point (pI) of 5.99, while wt-ANG is positively
charged with an isoelectric point of 9.73. With the addition of each GFP11 tag, the theoretical pI
of each fusion protein is gradually reduced to 9.57, 9.41 and 9.10 for NA1C, NA2C and NA4C,
respectively. We must also recognize that wt-ANG is internalized via a cell-surface receptor
through an 8-amino-acid loop, in which 3 residues carry a positive charge (Arg-65, His-64, Lys60). The modelled 3D structure showed that the GFP11 tag and this loop are located on the same
side of the fusion protein (Figure 18), which suggests that the GFP11 tag might have precluded
ANG’s native receptor-binding activity and led to this failed internalization result.
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a

b

Figure 18. Modelled 3D structures of (a) NA1C and (b) NA4C, highlighting ANG’s receptor binding site
(60Lys-Lys68) in blue and GFP11 tags in green. The GFP11 tags are located on the same side of the
receptor binding site, suggesting that they might interfere with the receptor binding activity of ANG.
Structures were obtained via the Robetta server and visualized using PyMOL.

The null result from the flow cytometry experiment offers ample room for growth in
future work. Currently, our utmost priority is to validate the internalization of NAxC proteins by
the target cells, which can be achieved through an anti-ANG immunostaining experiment on
incubated HeLaGFP1-10 cells. This experiment will determine whether NAxC failed to enter the
cells entirely, or if they entered the cells undetected, in the case that fluorescence signal was
below the instrument’s limit of detection. In addition, modifying the incubation conditions might
prove helpful, such as prolonging the incubation period to 24h instead of 2h, or increasing the
concentration of the fusion protein. These experiments will therefore elucidate whether the
cellular internalization activity of ANG is abolished by the addition of GFP11 tags.
Research significance
With these preliminary data, this protein engineering project in the Dickson Lab is a truly
exciting initiative in uncharted waters. Broadly, the project successfully laid out key features of a
split-GFP reporting system for ANG, which is a novel assay for many reasons. First, ANG
uptake has only been characterized in fixed cells via immunostaining.50,55,100 While
immunostaining is a convenient method to examine ANG uptake, it is only compatible with cells
that can withstand rigorous fixing and staining procedures. Cells undergoing mitosis, or stressed
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cells, are often ill-suited for immunostaining studies, and therefore have not been used to
characterize ANG uptake. Additionally, immunostaining on fixed cells precludes the possibility
to collect spatio-temporal data on live cells. These missing pieces of information are critical to
elucidate the mechanism of action of ANG.
In addition, our project utilizes a novel split GFP technology, which has yet to be tested
in systems like ours. Split GFP reporting systems have been used to study the cellular
distribution of other proteins; however, these proteins were endogenously transfected with
plasmid DNA, using either Lipofectamine88,89 or electroporation.98 Exogenously expressed
proteins, like ANG in this work, have not been studied using split fluorescence technology. This
motivates us to explore the compatibility of split GFP with ANG, as this reporting system, once
optimized, can add valuable insights to our current one-dimensional understanding of ANG
uptake. Specifically, our reporting system would be compatible with cells undergoing various
stages of the cell cycle, or cells experiencing various stress conditions, and can allow for realtime monitoring of ANG dynamics using confocal microscopy.
In sum, we have made exciting preliminary progress on constructing ANG-GFP11 fusion
proteins for use in ANG uptake studies. Three C-terminal fusion proteins have been
characterized with good ribonucleolytic activity and robust GFP restoration capacity. More data
collection is underway, which, hopefully, will demonstrate the compatibility of this reporting
system for ANG studies in various cellular environments. Once the system is optimized, it can
drastically accelerate multiple research directions in this field, as better characterization of ANG
will enable scientists to fully harness its activity and develop potential treatments for ANGrelated diseases.

52

REFERENCES
(1)

Fett, J. W.; Strydom, D. J.; Lobb, R. R.; Alderman, E. M.; Bethune, J. L.; Riordan, J. F.; Vallee, B.
L. Isolation and Characterization of Angiogenin, an Angiogenic Protein from Human Carcinoma
Cells. Biochemistry 1985, 24 (20), 5480–5486. https://doi.org/10.1021/bi00341a030.

(2)

Folkman, J.; Klagsbrun, M. Angiogenic Factors. Science (80-. ). 1987, 235 (4787), 442–447.
https://doi.org/10.1126/science.2432664.

(3)

Folkman, J. Tumor Angiogenesis: Therapeutic Implications. N. Engl. J. Med. 1971, 285 (21),
1182–1186.

(4)

Shapiro, R.; Strydom, D. J.; Olson, K. A.; Vallee, B. L. Isolation of Angiogenin from Normal
Human Plasma. Biochemistry 1987, 26 (16), 5141–5146. https://doi.org/10.1021/bi00390a037.

(5)

Spong, C.; Ghidini, A.; Sherer, D.; Pezzullo, J.; Ossandon, M.; Eglinton, G. Angiogenin: A
Marker for Preterm Delivery in Midtrimester Amniotic Fluid. Am. J. Obstet. Gynecol. 1997, 176
(2), 415–418.

(6)

Iłżecka, J. Cerebrospinal Fluid Angiogenin Level in Patients with Amyotrophic Lateral Sclerosis.
Acta Clin. Croat. 2008, 47 (2), 77–79.

(7)

Strydom, D. J.; Fett, J. W.; Lobb, R. R.; Alderman, E. M.; Bethune, J. L.; Riordan, J. F.; Vallee, B.
L. Amino Acid Sequence of Human Tumor Derived Angiogenin1’. Biochemistry 1985, 24 (20),
5486–5494.

(8)

Leonidas, D. D.; Shapiro, R.; Allen, S. C.; Subbarao, G. V; Veluraja, K.; Ravi Acharya, K.
Refined Crystal Structures of Native Human Angiogenin and Two Active Site Variants:
Implications for the Unique Functional Properties of an Enzyme Involved in Neovascularisation
During Tumour Growth. J. Mol. Biol. 1999, 285 (3), 1209–1233.

(9)

Sheng, J.; Xu, Z. Three Decades of Research on Angiogenin: A Review and Perspective. Acta
Biochim. Biophys. Sin. (Shanghai). 2016, 48 (5), 399–410. https://doi.org/10.1093/abbs/gmv131.

(10)

Koczera, P.; Martin, L.; Marx, G.; Schuerholz, T. The Ribonuclease A Superfamily in Humans:
Canonical RNases as the Buttress of Innate Immunity. Int. J. Mol. Sci. 2016, 17 (8), 1278.
53

https://doi.org/10.3390/ijms17081278.
(11)

Lee, F. S.; Shapiro, R.; Vallee, B. L. Tight-Binding Inhibition of Angiogenin and Ribonuclease A
by Placental Ribonuclease Inhibitor. Biochemistry 1989, 28 (1), 225–230.
https://doi.org/10.1021/bi00427a031.

(12)

Russo, N.; Ravi Acharyat, K.; Vallee, B. L.; Shapiro, R. A Combined Kinetic and Modeling Study
of the Catalytic Center Subsites of Human Angiogenin. Biochemistry 1996, 93 (2), 804–808.

(13)

Ravi Acharya, K.; Shapirot, R.; Riordant, J. F.; Valleei, B. L. Crystal Structure of Bovine
Angiogenin at 1.5-A Resolution. Biochemistry 1995, 92 (7), 2949–2953.

(14)

Shapiro, R. Structural Features That Determine the Enzymatic Potency and Specificity of Human
Angiogenin: Threonine-80 and Residues 58-70 and 116-123. Biochemistry 1998, 37 (19), 6847–
6856. https://doi.org/10.1021/bi9800146.

(15)

Hu, G.-F.; Chang, S.-I.; Riordan, J. F.; Vallee, B. L. An Angiogenin-Binding Protein from
Endothelial Cells. Proc. Natl. Acad. Sci. USA 1991, 88 (6), 2227–2231.

(16)

Shapiro, R.; Riordan, J. F.; Vallee, B. L. Characteristic Ribonucleolytic Activity of Human
Angiogenin1. Biochemistry 1986, 25 (12), 3527–3532.

(17)

Sharma, G. S.; Kumar, T.; Singh, L. R. N-Homocysteinylation Induces Different Structural and
Functional Consequences on Acidic and Basic Proteins. PLoS One 2014, 9 (12), e116386.
https://doi.org/10.1371/journal.pone.0116386.

(18)

Crabtree, B.; Thiyagarajan, N.; Prior, S. H.; Wilson, P.; Iyer, S.; Ferns, T.; Shapiro, R.; Brew, K.;
Subramanian, V.; Acharya, K. R. Characterization of Human Angiogenin Variants Implicated in
Amyotrophic Lateral Sclerosis. Biochemistry 2007, 46, 11810–11818.
https://doi.org/10.1021/bi701333h.

(19)

Kieran, D.; Sebastia, J.; Greenway, M. J.; King, M. A.; Connaughton, D.; Concannon, C. G.;
Fenner, B.; Hardiman, O.; Prehn, J. H. M. Control of Motoneuron Survival by Angiogenin. J.
Neurosci. 2008, 28 (52), 14056–14061. https://doi.org/10.1523/JNEUROSCI.3399-08.2008.

(20)

Koutroubakis, I. E.; Xidakis, C.; Karmiris, K.; Sfiridaki, A.; Kandidaki, E.; Kouroumalis, E. A.
54

Serum Angiogenin in Inflammatory Bowel Disease. Dig. Dis. Sci. 2004, 49 (11), 1758–1762.
https://doi.org/10.1007/s10620-004-9565-4.
(21)

Hooper, L. V; Hong, C. Angiogenins: A New Class of Microbicidal Proteins Involved in Innate
Immunity. Nat. Immunol. 2003, 4 (3), 269–273. https://doi.org/10.1038/ni888.

(22)

Lee, H.; Lee, I.; Kang, T.; Jeong, G.; Chang, S. Angiogenin Is Involved in Morphological Changes
and Angiogenesis in the Ovary. Biochem. Biophys. Res. Commun. 1999, 257 (1), 182–186.

(23)

Kishimoto, K.; Liu, S.; Tsuji, T.; Olson, K. A.; Hu, G.-F. Endogenous Angiogenin in Endothelial
Cells Is a General Requirement for Cell Proliferation and Angiogenesis. Oncogene 2005, 24 (3),
445–456. https://doi.org/10.1038/sj.onc.1208223.

(24)

Greenway, M.; Andersen, P.; Russ, C.; Ennis, S.; Cashman, S.; Donaghy, C.; Patterson, V.;
Swingler, R.; Kieran, D.; Prehn, J.; et al. ANG Mutations Segregate with Familial
and’sporadic’amyotrophic Lateral Sclerosis. Nat. Genet. 2006, 38 (4), 411–413.

(25)

Wu, D.; Yu, W.; Kishikawa, H.; Folkerth, R. D.; Iafrate, A. J.; Shen, Y.; Xin, W.; Sims, K.; Hu, G.
F. Angiogenin Loss-of-Function Mutations in Amyotrophic Lateral Sclerosis. Ann. Neurol. Off. J.
Am. Neurol. Assoc. Child Neurol. Soc. 2007, 62 (6), 609–617. https://doi.org/10.1002/ana.21221.

(26)

Van Es, M. A.; Schelhaas, H. J.; Van Vught, P. W. J.; Ticozzi, N.; Andersen, P. M.; Groen, E. J.
N.; Schulte, C.; Blauw, H. M.; Koppers, M.; Diekstra, F. P.; et al. Angiogenin Variants in
Parkinson Disease and Amyotrophic Lateral Sclerosis. Ann. Neurol. 2011, 70 (6), 964–973.
https://doi.org/10.1002/ana.22611.

(27)

Hallahan, T. W.; Shapiro, R.; Strydom, D. J.; Vallee, B. L. Importance of Asparagine-61 and
Asparagine-109 to the Angiogenic Activity of Human Angiogenin. Biochemistry 1992, 31 (34),
8022–8029.

(28)

Hallahan, T. W.; Shapiro, R.; Vallee, B. L. Dual Site Model for the Organogenic Activity of
Angiogenin. Proc. Natl. Acad. Sci. USA 1991, 88 (6), 2222–2226.

(29)

Yu, W.; Goncalves, K. A.; Li, S.; Kishikawa, H.; Sun, G.; Yang, H.; Vanli, N.; Wu, Y.; Jiang, Y.;
Hu, M. G.; et al. Plexin-B2 Mediates Physiologic and Pathologic Functions of Angiogenin. Cell
55

2017, 171 (4), 849–864. https://doi.org/10.1016/j.cell.2017.10.005.
(30)

Hu, G.-F.; Riordan, J. F.; Vallee, B. L. A Putative Angiogenin Receptor in AngiogeninResponsive Human Endothelial Cells. Biochemistry 1997, 94 (6), 2204–2209.

(31)

Gao, X.; Xu, Z. Mechanisms of Action of Angiogenin. Acta Biochim Biophys Sin 2008, 40 (7),
619–624. https://doi.org/10.1111/j.1745-7270.2008.

(32)

Lyons, S. M.; Fay, M. M.; Akiyama, Y.; Anderson, P. J.; Ivanov, P. RNA Biology of Angiogenin:
Current State and Perspectives. RNA Biol. 2017, 14 (2), 171–178.
https://doi.org/10.1080/15476286.2016.1272746.

(33)

Harper, J. W.; Vallee, B. L. A Covalent Angiogenin/Ribonuclease Hybrid with a Fourth Disulfide
Bond Generated by Regional Mutagenesis. Biochemistry 1989, 28 (4), 1875–1884.
https://doi.org/10.1021/bi00430a067.

(34)

Hu, G.-F.; Strydom, D. J.; Fett, J. W.; Riordan, J. F.; Vallee, B. L. Actin Is a Binding Protein for
Angiogenin. Proc. Nati. Acad. Sci. USA 1993, 90 (4), 1217–1221.

(35)

Hu, G.-F.; Riordan, J. F.; Vallee, B. L. Angiogenin Promotes Invasiveness of Cultured Endothelial
Cells by Stimulation of Cell-Associated Proteolytic Activities. Proc. Natl. Acad. Sci. U. S. A.
1994, 91 (25), 12096–12100.

(36)

Soncin, F. Angiogenin Supports Endothelial and Fibroblast Cell Adhesion. Cell Biol. 1992, 89 (6),
2232–2236.

(37)

Saxena, S. K.; Rybak, S. M.; Winkler, G.; Meade, H. M.; McGray, P.; Youle, R. J.; Ackerman, E.
J. Comparison of RNases and Toxins upon Injection into Xenopus Oocytes. J. Biol. Chem. 1991,
266 (31), 21208–21214. https://doi.org/10.1016/s0021-9258(18)54842-0.

(38)

Saxena, S. K.; Rybak, S. M.; Davey, R. T.; Youle, R. J.; Ackerman, E. J. Angiogenin Is a
Cytotoxic, TRNA-Specific Ribonuclease in the RNase A Superfamily. J. Biol. Chem. 1992, 267
(30), 21982–21986. https://doi.org/10.1016/s0021-9258(19)36710-9.

(39)

Haigis, M. C.; Kurten, E. L.; Raines, R. T. Ribonuclease Inhibitor as an Intracellular Sentry.
Nucleic Acids Res. 2003, 31 (3), 1024–1032. https://doi.org/10.1093/nar/gkg163.
56

(40)

Shapiro, R.; Vallee, B. L. Human Placental Ribonuclease Inhibitor Abolishes Both Angiogenic
and Ribonucleolytic Activities of Angiogenin. Proc. Natl. Acad. Sci. U. S. A. 1987, 84 (8), 2238–
2241. https://doi.org/10.1073/pnas.84.8.2238.

(41)

Pizzo, E.; Sarcinelli, C.; Sheng, J.; Fusco, S.; Formiggini, F.; Netti, P.; Yu, W.; D’Alessio, G.; Hu,
G. F. Ribonuclease/Angiogenin Inhibitor 1 Regulates Stressinduced Subcellular Localization of
Angiogenin to Control Growth and Survival. J. Cell Sci. 2013, 126 (18), 4308–4319.
https://doi.org/10.1242/jcs.134551.

(42)

Emara, M. M.; Ivanov, P.; Hickman, T.; Dawra, N.; Tisdale, S.; Kedersha, N.; Hu, G. F.;
Anderson, P. Angiogenin-Induced TRNA-Derived Stress-Induced RNAs Promote Stress-Induced
Stress Granule Assembly. J. Biol. Chem. 2010, 285 (14), 10959–10968.
https://doi.org/10.1074/jbc.M109.077560.

(43)

Anderson, P.; Kedersha, N.; Ivanov, P. Stress Granules, P-Bodies and Cancer. Biochim. Biophys.
Acta - Gene Regul. Mech. 2015, 1849 (7), 861–870. https://doi.org/10.1016/j.bbagrm.2014.11.009.

(44)

Fu, H.; Feng, J.; Liu, Q.; Sun, F.; Tie, Y.; Zhu, J.; Xing, R.; Sun, Z.; Zheng, X. Stress Induces
TRNA Cleavage by Angiogenin in Mammalian Cells. FEBS Lett. 2009, 583 (2), 437–442.
https://doi.org/10.1016/j.febslet.2008.12.043.

(45)

Czech, A.; Wende, S.; Mörl, M.; Pan, T.; Ignatova, Z. Reversible and Rapid Transfer-RNA
Deactivation as a Mechanism of Translational Repression in Stress. PLoS Genet. 2013, 9 (8),
e1003767. https://doi.org/10.1371/journal.pgen.1003767.

(46)

Saikia, M.; Krokowski, D.; Guan, B. J.; Ivanov, P.; Parisien, M.; Hu, G. F.; Anderson, P.; Pan, T.;
Hatzoglou, M. Genome-Wide Identification and Quantitative Analysis of Cleaved TRNA
Fragments Induced by Cellular Stress. J. Biol. Chem. 2012, 287 (51), 42708–42725.
https://doi.org/10.1074/jbc.M112.371799.

(47)

Thompson, D. M.; Lu, C.; Green, P. J.; Parker, R. TRNA Cleavage Is a Conserved Response to
Oxidative Stress in Eukaryotes. RNA 2008, 14 (10), 2095–2103.
https://doi.org/10.1261/rna.1232808.
57

(48)

Saikia, M.; Jobava, R.; Parisien, M.; Putnam, A.; Krokowski, D.; Gao, X.-H.; Guan, B.-J.; Yuan,
Y.; Jankowsky, E.; Feng, Z.; et al. Angiogenin-Cleaved TRNA Halves Interact with Cytochrome
c, Protecting Cells from Apoptosis during Osmotic Stress. Mol. Cell. Biol. 2014, 34 (13), 2450–
2463. https://doi.org/10.1128/MCB.00136-14.

(49)

Peng, Y.; Li, L.; Huang, M.; Duan, C.; Zhang, L.; Chen, J. Angiogenin Interacts with
Ribonuclease Inhibitor Regulating PI3K/AKT/MTOR Signaling Pathway in Bladder Cancer Cells.
Cell. Signal. 2014, 26 (12), 2782–2792. https://doi.org/10.1016/j.cellsig.2014.08.021.

(50)

Moroianu, J.; Riordan, J. F. Nuclear Translocation of Angiogenin in Proliferating Endothelial
Cells Is Essential to Its Angiogenic Activity. Cell Biol. 1994, 91 (5), 1677–1681.

(51)

Moroianu, J.; Riordan, J. F. Identification of the Nucleolar Targeting Signal of Human
Angiogenin. Biochem. Biophys. Res. Commun. 1994, 203 (3), 1765–1772.
https://doi.org/10.1006/bbrc.1994.2391.

(52)

Hu, G.; Xu, C.; Riordan, J. F. Human Angiogenin Is Rapidly Translocated to the Nucleus of
Human Umbilical Vein Endothelial Cells and Binds to DNA. J. Cell. Biochem. 2000, 76 (3), 452–
462.

(53)

Li, R.; Riordan, J.; Hu, G. Nuclear Translocation of Human Angiogenin in Cultured Human
Umbilical Artery Endothelial Cells Is Microtubule and Lysosome Independent. Biochem. Biophys.
Res. Commun. 1997, 238 (2), 305–312.

(54)

Tsuji, T.; Sun, Y.; Kishimoto, K.; Olson, K. A.; Liu, S.; Hirukawa, S.; Hu, G.-F. Angiogenin Is
Translocated to the Nucleus of HeLa Cells and Is Involved in Ribosomal RNA Transcription and
Cell Proliferation. Cancer Res. 2005, 65 (4), 1352–1360.

(55)

Thiyagarajan, N.; Ferguson, R.; Subramanian, V.; Acharya, K. R. Structural and Molecular
Insights into the Mechanism of Action of Human Angiogenin-ALS Variants in Neurons. Nat.
Commun. 2012, 3 (1), 1–14. https://doi.org/10.1038/ncomms2126.

(56)

Hu, G.-F. Neomycin Inhibits Angiogenin-Induced Angiogenesis. Natl. Acad Sci. 1998, 95 (17),
9791–9795.
58

(57)

Hirukawa, S.; Olson, K. A.; Tsuji, T.; Hu, G.-F. Neamine Inhibits Xenografic Human Tumor
Growth and Angiogenesis in Athymic Mice. Clin. Cancer Res. 2005, 11 (24), 8745–8752.
https://doi.org/10.1158/1078-0432.CCR-05-1495.

(58)

Nilsson, U. W.; Abrahamsson, A.; Dabrosin, C. Angiogenin Regulation by Estradiol in Breast
Tissue: Tamoxifen Inhibits Angiogenin Nuclear Translocation and Antiangiogenin Therapy
Reduces Breast Cancer Growth In Vivo. Clin. Cancer Res. 2010, 16 (14), 3659–3669.
https://doi.org/10.1158/1078-0432.CCR-10-0501.

(59)

Xu, Z. P.; Tsuji, T.; Riordan, J. F.; Hu, G. F. The Nuclear Function of Angiogenin in Endothelial
Cells Is Related to RRNA Production. Biochem. Biophys. Res. Commun. 2002, 294 (2), 287–292.
https://doi.org/10.1016/S0006-291X(02)00479-5.

(60)

Xu, Z.-P.; Tsuji, T.; Riordan, J. F.; Hu, G.-F. Identification and Characterization of an
Angiogenin-Binding DNA Sequence That Stimulates Luciferase Reporter Gene Expression. ACS
Publ. 2003, 42 (1), 121–128. https://doi.org/10.1021/bi020465x.

(61)

Sheng, J.; Yu, W.; Gao, X.; Xu, Z.; Hu, G. F. Angiogenin Stimulates Ribosomal RNA
Transcription by Epigenetic Activation of the Ribosomal DNA Promoter. J. Cell. Physiol. 2014,
229 (4), 521–529. https://doi.org/10.1002/jcp.24477.

(62)

Mayer, C.; Neubert, M.; Grummt, I. The Structure of NoRC‐associated RNA Is Crucial for
Targeting the Chromatin Remodelling Complex NoRC to the Nucleolus. EMBO Rep. 2008, 9 (8),
774–780. https://doi.org/10.1038/embor.2008.109.

(63)

Hoang, T. T.; Raines, R. T. Molecular Basis for the Autonomous Promotion of Cell Proliferation
by Angiogenin. Nucleic Acids Res. 2017, 45 (2), 818–831. https://doi.org/10.1093/nar/gkw1192.

(64)

Piccoli, R.; Olson, K. A.; Vallee, B. L.; Fett, J. W. Chimeric Anti-Angiogenin Antibody CAb 262F Inhibits the Formation of Human Breast Cancer Xenografts in Athymic Mice. Proc. Natl.
Acad. Sci. U. S. A. 1998, 95 (8), 4579–4583. https://doi.org/10.1073/pnas.95.8.4579.

(65)

Gho, Y. S.; Chae, C. B. Anti-Angiogenin Activity of the Peptides Complementary to the ReceptorBinding Site of Angiogenin. J. Biol. Chem. 1997, 272 (39), 24294–24299.
59

https://doi.org/10.1074/jbc.272.39.24294.
(66)

Olson, K. A.; Byers, H. R.; Key, M. E.; Fett, J. W. Prevention of Human Prostate Tumor
Metastasis in Athymic Mice by Antisense Targeting of Human Angiogenin. Clin. Cancer Res.
2001, 7 (11), 3598–3605.

(67)

Kao, R. Y. T.; Jenkins, J. L.; Olson, K. A.; Key, M. E.; Fett, J. W.; Shapiro, R. A Small-Molecule
Inhibitor of the Ribonucleolytic Activity of Human Angiogenin That Possesses Antitumor
Activity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (15), 10066–10071.
https://doi.org/10.1073/pnas.152342999.

(68)

Ibaragi, S.; Yoshioka, N.; Li, S.; Hu, M. G.; Hirukawa, S.; Sadow, P. M.; Hu, G. F. Neamine
Lnhibits Prostate Cancer Growth by Suppressing Angiogenin-Mediated RRNA Transcription.
Clin. Cancer Res. 2009, 15 (6), 1981–1988. https://doi.org/10.1158/1078-0432.CCR-08-2593.

(69)

Prendergast, F.; Mann, K. G. Chemical and Physical Properties of Aequorin and the Green
Fluorescent Protein Isolated from Aequorea Forskalea. Biochemistry 1978, 17 (17), 3448–3453.

(70)

Shimomura, O. Structure of the Chromaphore of Aequorea Green Fluorescent Protein. Febs Lett.
1979, 104 (2), 220–222.

(71)

Chalfie, M.; Tu, Y.; Euskirchen, G.; Ward, W. W.; Prasher, D. C. Green Fluorescent Protein as a
Marker for Gene Expression. Science (80-. ). 1994, 263 (5148), 802–805.

(72)

Zimmer, M. Green Fluorescent Protein (GFP): Applications, Structure, and Related Photophysical
Behavior. Chem. Rev. 2002, 102 (3), 759–781. https://doi.org/10.1021/cr010142r.

(73)

Morin, J. G.; Hastings, J. W. Energy Transfer in a Bioluminescent System. J. Cell. Physiol. 1971,
77 (3), 313–318. https://doi.org/10.1002/jcp.1040770305.

(74)

Ward, W. W. Energy Transfer Processes in Bioluminescence; Springer US, 1979.
https://doi.org/10.1007/978-1-4684-3551-1_1.

(75)

Heim, R.; Tsien, R. Y. Engineering Green Fluorescent Protein for Improved Brightness, Longer
Wavelengths and Fluorescence Resonance Energy Transfer. Curr. Biol. 1996, 6 (2), 178–182.
https://doi.org/10.1016/S0960-9822(02)00450-5.
60

(76)

Ormö, M.; Cubitt, A.; Kallio, K.; Gross, L.; Tsien, R.; Remington, S. Crystal Structure of the
Aequorea Victoria Green Fluorescent Protein. Science (80-. ). 1996, 273 (5280), 1392–1395.

(77)

Barondeau, D. P.; Putnam, C. D.; Kassmann, C. J.; Tainer, J. A.; Getzoff, E. D. Mechanism and
Energetics of Green Fluorescent Protein Chromophore Synthesis Revealed by Trapped
Intermediate Structures. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (21), 12111–12116.

(78)

Yang, F.; Moss, L.; Phillips, G. The Molecular Structure of Green Fluorescent Protein. Nat.
Biotechnol. 1996, 14 (10), 1246–1251.

(79)

Zhang, L.; Patel, H. N.; Lappe, J. W.; Wachter, R. M. Reaction Progress of Chromophore
Biogenesis in Green Fluorescent Protein. J. Am. Chem. Soc. 2006, 128 (14), 4766–4772.
https://doi.org/10.1021/ja0580439.

(80)

Bokman, S.; Ward, W. Renaturation of Aequorea Green-Fluorescent Protein. Biochem. Biophys.
Res. Commun. 1981, 101 (4), 1372–1380.

(81)

Lippincott-Schwartz, J.; Patterson, G. H. Development and Use of Fluorescent Protein Markers in
Living Cells. Science (80-. ). 2003, 300 (5616), 87–91.

(82)

Bastaiens, P.; Pepperok, R. Observing Proteins in Their Natural Habitat: The Living Cell. Trends
Biochem. Sci. 2000, 25 (12), 631–637.

(83)

Hink, M.; Griep, R.; Borst, J.; Van Hoek, A.; Eppink, M.; Schots, A.; Visser, A. Structural
Dynamics of Green Fluorescent Protein Alone and Fused with a Single Chain Fv Protein. J. Biol.
Chem. 2000, 275 (23), 17556–17650.

(84)

Zhang, G.; Gurtu, V.; Kain, S. R. An Enhanced Green Fluorescent Protein Allows Sensitive
Detection of Gene Transfer in Mammalian Cells. Biochem. Biophys. Res. Commun. 1996, 227 (3),
707–711. https://doi.org/10.1006/bbrc.1996.1573.

(85)

Pédelacq, J.-D.; Cabantous, S.; Tran, T.; Terwilliger, T. C.; Waldo, G. S. Engineering and
Characterization of a Superfolder Green Fluorescent Protein. Nat. Biotechnol. 2006, 24 (1), 79–88.
https://doi.org/10.1038/nbt1172.

(86)

Pedelacq, J. D.; Cabantous, S. Development and Applications of Superfolder and Split Fluorescent
61

Protein Detection Systems in Biology. Int. J. Mol. Sci. 2019, 20 (14), 3479.
https://doi.org/10.3390/ijms20143479.
(87)

Cabantous, S.; Terwilliger, T. C.; Waldo, G. S. Protein Tagging and Detection with Engineered
Self-Assembling Fragments of Green Fluorescent Protein. Nat. Biotechnol. 2005, 23 (1), 102–107.
https://doi.org/10.1038/nbt1044.

(88)

Kamiyama, D.; Sekine, S.; Barsi-Rhyne, B.; Hu, J.; Chen, B.; Gilbert, L. A.; Ishikawa, H.;
Leonetti, M. D.; Marshall, W. F.; Weissman, J. S.; et al. Versatile Protein Tagging in Cells with
Split Fluorescent Protein. Nat. Commun. 2016, 7 (1), 1–9. https://doi.org/10.1038/ncomms11046.

(89)

Hyun, S.-I.; Maruri-Avidal, L.; Moss, B. Topology of Endoplasmic Reticulum-Associated Cellular
and Viral Proteins Determined with Split-GFP. Traffic 2015, 16 (7), 787–795.
https://doi.org/10.1111/tra.12281.

(90)

Ruan, L.; Zhou, C.; Jin, E.; Kucharavy, A.; Zhang, Y.; Wen, Z.; Florens, L.; Li, R. Cytosolic
Proteostasis through Importing of Misfolded Proteins into Mitochondria. Nature 2017, 543 (7645),
443–446. https://doi.org/10.1038/nature21695.

(91)

Palmer, E.; Freeman, T. Investigation into the Use of C- and N-Terminal GFP Fusion Proteins for
Subcellular Localization Studies Using Reverse Transfection Microarrays. Comp. Funct.
Genomics 2004, 5 (4), 342–353. https://doi.org/10.1002/cfg.405.

(92)

Ikebe, M.; Kambara, T.; Stafford, W.; Sata, M.; Katayama, E.; Ikebe, R. A Hinge at the Central
Helix of the Regulatory Light Chain of Myosin Is Critical for Phosphorylation-Dependent
Regulation of Smooth Muscle Myosin Motor Activity. J. Biol. Chem. 1998, 273 (28), 17702–
17707.

(93)

Argos, P. An Investigation of Oligopeptides Linking Domains in Protein Tertiary Structures and
Possible Candidates for General Gene Fusion. J. Mol. Biol. 1990, 211 (4), 943–958.

(94)

Chen, X.; Zaro, J. L.; Shen, W. C. Fusion Protein Linkers: Property, Design and Functionality.
Adv. Drug Deliv. Rev. 2013, 65 (10), 1357–1369. https://doi.org/10.1016/j.addr.2012.09.039.

(95)

Song, Y.; DiMaio, F.; Wang, R. Y. .; Kim, D.; Miles, C.; Brunette, T. J.; Thompson, J.; Baker, D.
62

High-Resolution Comparative Modeling with RosettaCM. Structure 2013, 21 (10), 1735–1742.
(96)

Pucci, F.; Kwasigroch, J. M.; Rooman, M. SCooP: An Accurate and Fast Predictor of Protein
Stability Curves as a Function of Temperature. Bioinformatics 2017, 33 (21), 3415–3422.
https://doi.org/10.1093/bioinformatics/btx417.

(97)

Dion-Kirschner, S. Characterizing the Dynamics of Angiogenin Uptake and Cellular Localization
with a Split-GFP System, Lawrence University, 2020.

(98)

Leonetti, M. D.; Sekine, S.; Kamiyama, D.; Weissman, J. S.; Huang, B.; Babcock, H. P.; De
Camilli, P. A Scalable Strategy for High-Throughput GFP Tagging of Endogenous Human
Proteins. Proc. Natl. Acad. Sci. U. S. A. 2016, 113 (23), E3501–E3508.
https://doi.org/10.1073/pnas.1606731113.

(99)

Qin, Z.; Buehler, M. J. Molecular Dynamics Simulation of the α-Helix to β-Sheet Transition in
Coiled Protein Filaments: Evidence for a Critical Filament Length Scale. Phys. Rev. Lett. 2010,
104 (19), 198304. https://doi.org/10.1103/PhysRevLett.104.198304.

(100) Ferguson, R.; Subramanian, V. The Cellular Uptake of Angiogenin, an Angiogenic and
Neurotrophic Factor Is through Multiple Pathways and Largely Dynamin Independent. PLoS One
2018, 13 (2), e0193302. https://doi.org/10.1371/journal.pone.0193302.

PyMOL figures created with the PyMOL Molecular Graphics System, Version 2.4.2 Schrödinger, LLC.
All other figures created with BioRender.com.

63

APPENDICES
Appendix 1. Amino acid sequence of ANG-GFP11 fusion proteins.
Protein Sequence
N1AC
MRDHMVLHEYVNAAGITGSSGGQDNSRYTHFLTQHYDAKPQGRDDRYCE
SIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTC
KLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP*
N2AC
MRDHMVLHEYVNAAGITGGSGGRDHMVLHEYVNAAGITGSSGGQDNSRY
THFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICE
NKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACEN
GLPVHLDQSIFRRP*
N4Ac
MRDHMVLHEYVNAAGITGGSGGRDHMVLHEYVNAAGITGGSGGRDHMV
LHEYVNAAGITGGSGGRDHMVLHEYVNAAGITGSSGGQDNSRYTHFLTQH
YDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPH
RENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLD
QSIFRRP*
NA1C
MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNK
RSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRN
VVVACENGLPVHLDQSIFRRPGSSGRDHMVLHEYVNAAGITGGSGG*
NA2C
MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNK
RSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRN
VVVACENGLPVHLDQSIFRRPGSSGRDHMVLHEYVNAAGITGGSGGRDHM
VLHEYVNAAGITGGSGG*
NA4C
MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNK
RSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRN
VVVACENGLPVHLDQSIFRRPGSSGRDHMVLHEYVNAAGITGGSGGRDHM
VLHEYVNAAGITGGSGGRDHMVLHEYVNAAGITGGSGGRDHMVLHEYVN
AAGIT*

Appendix 2. List of primers and Geneblock.

1
2
3
4
5
6

5’-3’ sequence
gcaccaccaccaccac
tatgtatatctccttcttaaagttaaacaaaattatttctag
gtggtggtggtggtgcTTACGGACGACGGAAAATTGA
CTGATCCAAGTGGACAGG
gaaggagatatacataATGCGGGACCATATGGTCCTGC
ACGAATATGTCAATGC
gaaggagatatacataATGAGGGATCACATGGTACTCC
ATGAGTACGTGAACGC
ctagaaataattttgtttaactttaagaaggagatatacataATGAGAG
ACCACATGGTTTTGCATGAGTATGTGAACGCG
G
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Name
Gibson pET-22b FP
Gibson pET-22b RP
Gibson NxAC RP
Gibson N1AC FP
Gibson N2AC FP
Gibson N4AC FP

7
8
9
10
11
12
13
14
15
16

17

18

gaaggagatatacataATGCAGGATAACTCCAGGTACA
CACACTTCCTGACCC
gtggtggtggtggtgcTTATCCGCCCGACCCACCAGTT
ATACCCG
gtggtggtggtggtgcTTAGCCACCTGATCCGCCAGTA
ATGCCAGC
gtggtggtggtggtgcTTAGGTGATACCGGCAGCATTG
ACATATTCGTGCAGGACC
TAATACGACTCACTATAGGG
GCTAGTTATTGCTCAGCGG
gcgaaattaatacgactcactatagggg
caaggggttatgctagttattgc
CTTGCAAGCTACATGGAGGTTC
GACCCACCAGTTATACCCGC
ATGAGAGACCACATGGTTTTGCATGAGTATGT
GAACGCGGCGGGTATAACTGGTGGGTCGGGC
GGACGAGACCATATGGTGCTTCACGAATACGT
AAACGCAGCTGGCATTACTGGCGGATCAGGTG
GCAGGGATCACATGGTACTCCATGAGTACGTG
AACGCTGCTGGAATCACAGGCGGTAGCGGCG
GTCGGGACCATATGGTCCTGCACGAATATGTC
AATGCTGCCGGTATCACCGGAAGTTCCGGCGG
CCAGGATAACTCCAGGTACACACACTTCCTGA
CCCAGCACTATGATGCCAAACCACAGGGCCGG
GATGACAGATACTGTGAAAGCATCATGCGCCG
TCGCGGCCTGACCTCACCCTGCAAAGACATCA
ACACATTTATTCATGGCAACAAGCGCAGCATC
AAGGCCATCTGTGAAAACAAGAATGGAAACC
CTCACCGCGAAAACCTGCGCATTAGCAAGTCT
TCTTTCCAGGTCACCACTTGCAAGCTACATGG
AGGTTCCCCCTGGCCTCCATGCCAGTACCGAG
CCACAGCGGGGTTCAGAAACGTTGTTGTTGCT
TGTGAAAATGGCTTACCTGTCCACTTGGATCA
GTCAATTTTCCGTCGTCCGTAA
ATGCAGGATAACTCCAGGTACACACACTTCCT
GACCCAGCACTATGATGCCAAACCACAGGGCC
GGGATGACAGATACTGTGAAAGCATCATGCGC
CGTCGCGGCCTGACCTCACCCTGCAAAGACAT
CAACACATTTATTCATGGCAACAAGCGCAGCA
TCAAGGCCATCTGTGAAAACAAGAATGGAAA
CCCTCACCGCGAAAACCTGCGCATTAGCAAGT
CTTCTTTCCAGGTCACCACTTGCAAGCTACATG
GAGGTTCCCCCTGGCCTCCATGCCAGTACCGA
GCCACAGCGGGGTTCAGAAACGTTGTTGTTGC
TTGTGAAAATGGCTTACCTGTCCACTTGGATC
AGTCAATTTTCCGTCGTCCGGGAAGTTCCGGC
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Gibson NAxC FP
Gibson NA1C RP
Gibson NA2C RP
Gibson NA4C RP
Sequencing T7 promoter / FP
Sequencing T7 terminator / RP
Sequencing pET-22b
Sequencing pET-22b RP
Sequencing Internal ANG FP
Sequencing Internal GFP11 RP

Geneblock for NxAC

Geneblock for NAxC

AGAGACCACATGGTTTTGCATGAGTATGTGAA
CGCGGCGGGTATAACTGGTGGGTCGGGCGGAT
AA
FP = forward primer, RP = reverse primer

Appendix 3. Characterization of ribonucleolytic activity of all ANG variants.
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Appendix 3. Time-based characterization of the ribonucleolytic activity of (a) wt-ANG, or fusion proteins (b)
NA1C, (c) NA2C, and (d) NA4C towards a fluorogenic RNA substrate. Fluorescence signal (485nm excitation,
520nm emission) was measured for three different protein concentrations—0.75, 1.50 and 3.00µM. n=1.
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